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Abstract
Arthropod-borne viruses (arboviruses) are an important class of emerging pathogens that cause mortality and
morbidity worldwide. As obligate intracellular parasites with limited coding capacity, viruses must hijack host
factors to replicate while evading host detection. To date, no specific therapeutic interventions exist for
arboviruses and most lack FDA approved vaccines. This is in part due to a lack of understanding of viral-host
interactions. To identify host factors that impact infection, we performed a genome-wide RNAi screen in
Drosophila and identified 131 genes that affected infection of the mosquito-transmitted bunyavirus Rift Valley
Fever virus (RVFV). Dcp2, the catalytic component of the mRNA decapping machinery, and two decapping
activators, DDX6 and LSM7, were antiviral against disparate bunyaviruses in both insect cells and adult flies.
Bunyaviruses 5' cap their mRNAs by `cap-snatching' the 5' ends of poorly defined host mRNAs. We found
that RVFV cap-snatches the 5' ends of Dcp2 targeted mRNAs, including cell cycle related genes. Loss of Dcp2
allows increased viral transcription, while ectopic expression of Dcp2 impedes transcription. Furthermore,
arresting cells in late S/early G2 led to increased Dcp2 mRNA targets and increased RVFV replication.
Therefore, RVFV competes for the Dcp2-accessible mRNA pool, which is dynamically regulated and can
present a bottleneck for viral replication.
I extended these studies to mammalian cells and I found that the two known human decapping enzymes,
DCP2 and NUDT16, restrict RVFV replication. Since depletion of either gene impacted replication, this
suggests that DCP2 and NUDT16 are non-redundant. In human cells, I found that RVFV predominately cap-
snatches from mRNAs associated with translation, and the stability of these mRNAs is regulated by
decapping; furthermore, instability of these mRNAs is triggered by RVFV infection. I hypothesize that
translationally-associated genes, including ribosomal protein mRNAs, are selectively degraded during this
response to limit translation to prevent viral replication. These data suggest that a particular functional class of
mRNAs (translation-associated) can be coordinately regulated at the level of mRNA stability by decapping,
and that this may be used as a mechanism by cells to selectively regulate gene expression.
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ABSTRACT 
 
THE RNA DECAPPING MACHINERY IS A CONSERVED ANTI-BUNYAVIRAL 
RESTRICTION FACTOR 
 
Kaycie C. Hopkins 
Sara Cherry 
 
Arthropod-borne viruses (arboviruses) are an important class of emerging 
pathogens that cause mortality and morbidity worldwide. As obligate intracellular 
parasites with limited coding capacity, viruses must hijack host factors to replicate while 
evading host detection. To date, no specific therapeutic interventions exist for 
arboviruses and most lack FDA approved vaccines. This is in part due to a lack of 
understanding of viral-host interactions. To identify host factors that impact infection, we 
performed a genome-wide RNAi screen in Drosophila and identified 131 genes that 
affected infection of the mosquito-transmitted bunyavirus Rift Valley Fever virus (RVFV). 
Dcp2, the catalytic component of the mRNA decapping machinery, and two decapping 
activators, DDX6 and LSM7, were antiviral against disparate bunyaviruses in both insect 
cells and adult flies. Bunyaviruses 5’ cap their mRNAs by ‘cap-snatching’ the 5’ ends of 
poorly defined host mRNAs. We found that RVFV cap-snatches the 5’ ends of Dcp2 
targeted mRNAs, including cell cycle related genes. Loss of Dcp2 allows increased viral 
transcription, while ectopic expression of Dcp2 impedes transcription. Furthermore, 
arresting cells in late S/early G2 led to increased Dcp2 mRNA targets and increased 
RVFV replication. Therefore, RVFV competes for the Dcp2-accessible mRNA pool, 
which is dynamically regulated and can present a bottleneck for viral replication. 
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I extended these studies to mammalian cells and I found that the two known 
human decapping enzymes, DCP2 and NUDT16, restrict RVFV replication. Since 
depletion of either gene impacted replication, this suggests that DCP2 and NUDT16 are 
non-redundant. In human cells, I found that RVFV predominately cap-snatches from 
mRNAs associated with translation, and the stability of these mRNAs is regulated by 
decapping; furthermore, instability of these mRNAs is triggered by RVFV infection. I 
hypothesize that translationally-associated genes, including ribosomal protein mRNAs, 
are selectively degraded during this response to limit translation to prevent viral 
replication. These data suggest that a particular functional class of mRNAs (translation-
associated) can be coordinately regulated at the level of mRNA stability by decapping, 
and that this may be used as a mechanism by cells to selectively regulate gene 
expression. 
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TABLE OF CONTENTS 
 
I. INTRODUCTION…………………………………………………………………….……..….1 
1. Arthropod-borne viruses…………………………………………………..…..….…1 
2. Bunyaviruses and their replication……………………………………….….....…..2 
3. Cap-snatching as a mechanism of viral mRNA transcription…………..………..3 
4. Rift Valley Fever virus……………………………………………………………..…5 
5. RNAi screening as a mechanism to identify host-pathogen interactions……....6 
6. RNA degradation………………………………………………………………….….7 
 7. Processing Bodies……………………………………………………………….…..8 
 8. Aims of present studies……………………………………………………………...9 
 
II. MATERIALS AND METHODS……………………………………………..………..…….15 
 1. Cells, Viruses, Antibodies and Reagents……………………………………..….15 
2. RNAi…………………………………………………………..……………………...15 
3. siRNA………………………………………….……………………………………..15 
4. Viral Infections……………………………………………………...……………….16 
5. Immunofluorescence ……………………………………………….……………...16 
6. RNA analysis……………………………………………………..…………...…….16 
7. Cycloheximide treatment…………………………………………………………..17 
8. 5’RACE and cloning…………………………..……………..……………………..17 
9. BOWTIE analysis of human 5’RACE sequences………………...……………..17 
10. Exonuclease digest assay………………………………………………………..17 
11. Adult Fly Infections………………………………………………………………..18 
12. Cap radiolabeling of mRNA………………………………………………………18 
viii 
13. Oligonucleotide Sequences for Probes and RT-PCR…………………………18 
 
III. MRNA DECAPPING RESTRICTS BUNYAVIRAL REPLICATION BY LIMITING THE 
POOLS OF DCP2-ACCESSIBLE TARGETS FOR CAP-SNATCHING IN INSECTS....23 
1. Background……………………………………………………………………..….23 
2. Results……………………………………………………………………………...26 
3. Discussion…………………………………………………..……………………...39 
 
IV. THE MRNA DECAPPERS DCP2 AND NUDT16 LIMIT DISTINCT BUNYAVIRAL 
CAP-SNATCHING TARGETS TO RESTRICT INFECTION IN HUMANS………………61 
1. Background………………………………………………………………………...61 
2. Results…………………………………………………….………………………..63 
3. Discussion………………………………………………………………….……....69 
 
V. CONCLUDING REMARKS…………………………...……………………………...……84 
 1. Summary………………………………………………………………………..…...84 
 2. Future Directions………………………………………………………………..…..89 
 
VI. APPENDIX: TABLE 6.1……………………………………….…………………………..96 
 
VII. REFERENCES …………………………………………………………………………..102 
 
ix 
LIST OF TABLES 
 
Table 4.1. Cap-snatched sequences mapped back to human 5’UTRs………………..…83 
Table 6.1. Validated hits from a genome-wide RNAi screen for genes impacting RVFV 
replication in Drosophila ………………………………………………………………………96 
 
  
x 
 
LIST OF ILLUSTRATIONS 
 
Figure 1.1. Rift Valley Fever virus virion structure and coding strategy……………….....11 
Figure 1.2. Bunyaviral entry, replication and assembly……………………………….……12 
Figure 1.3. Bunyaviral cap-snatching…………………………………………………….…..13 
Figure 1.4. 5’ to 3’ mRNA decay in Eukaryotes………………………………………….….14 
Figure 3.1. Genome-wide RNAi screen for host factors that impact RVFV in 
Drosophila........................................................................................................................44 
Figure 3.2. Validated screen hits assigned to cellular functions based on informatics 
analysis…………………………………………………………………………………...……..45 
Figure 3.3. Decapping restricts RVFV replication in Drosophila cells………………........46 
Figure 3.4. Knockdown efficiency of dsRNAs……………………………………………….47 
Figure 3.5. Colocalization of Dcp1 with RVFV and Dcp2…………………………………..48 
Figure 3.6. Dcp2 restricts bunyaviruses in flies and mosquitoes……………………........49 
Figure 3.7. Supplemental information for whole animal experiments…………………….50 
Figure 3.8. Schematic of RVFV genomic RNA, mRNA and protein coding strategy……51 
Figure 3.9. Dcp2 does not directly degrade viral mRNA…………………………………...52 
Figure 3.10. Additional controls for Figure 3.9………………………………………………54 
Figure 3.11. Cell cycle RNAs are an enriched substrate for RVFV cap-snatching……...55 
Figure 3.12. Endogenous sequences cap-snatched by RVFV in Drosophila……………56 
Figure 3.13. Cell cycle arrest in late S/early G2 phase enhances bunyavirus 
replication........................................................................................................................58 
Figure 3.14. Representative northern blots as in Figure 3.13……………………….........59 
Figure 3.15. Ectopic expression of Dcp2 restricts RVFV replication……………………..60 
xi 
Figure 4.1. RVFV replication is increased by depletion of human mRNA decapping 
enzymes in U2OS cells………………………………………………………………………..74 
Figure 4.2. mRNA decapping enzymes are limiting for RVFV infection in humans…….75 
Figure 4.3. Histone mRNAs are incorporated into RVFV RNAs and limited by 
decapping........................................................................................................................76 
Figure 4.4. Ribosomal and translationally related mRNAs are targeted by both RVFV 
cap-snatching and mRNA decapping………………………………………………………...77 
Figure 4.5. RVFV infection triggers loss of Processing bodies in human cells………….79 
Figure 4.6. RVFV-dependent P body clearance occurs independent of autophagy…….81 
Figure 5.1. Decapping and cap-snatching machinery compete for cell cycle regulated 
mRNAs…………………………………………………………………………………….........94 
Figure 5.2. Decapping may restrict viral infection in humans through decay of core 
translation mRNAs……………………………………………………………………………..95 
 
 
1 
I. INTRODUCTION 
 
1. Arthropod-borne viruses  
Arthropod-borne viruses (arboviruses) are an emerging class of infectious 
diseases worldwide. Due to the vector-borne nature of their life cycle, arboviral infections 
present unique challenges to disease prevention and treatment. Climate change has 
increased the range of many species of mosquitoes capable of transmitting these 
infections, and introduction of nonnative arboviruses across the Atlantic has already 
occurred in at least one instance (West Nile virus) (71, 96). The absence of therapeutics 
or FDA approved vaccines for these diseases is driven in part by our lack of 
understanding of their replication strategies and host interactions, thus necessitating 
increased research.  
Arboviruses are a major cause of human and vertebrate morbidity and mortality 
globally. These viruses replicate in a vertebrate host in the wild (the reservoir), often a 
small mammal, such as a rodent, causing limited to no pathology. Hematophagous 
arthropods, such as ticks or mosquitoes, then bite these infected vertebrates and 
become infected. The virus replicates to high titers while causing limited to no pathology 
in the insect. The insect becomes infected for life, infecting vertebrate hosts upon blood 
feeding. While this lifecycle often is limited in its pathology to both host (vertebrate) and 
vector (arthropod) species, incidental infections of so called “dead-end” or “off-target” 
hosts can occur; these infections are typically in livestock or humans, and do not result 
in retransmission to another biting insect, due to limited serum viral titers (139). Unlike 
arboviral reservoir species, incidental infections may result in severe pathology.  
 Three main classes of arboviruses exist: 1) Flaviviruses, such as Dengue and 
West Nile virus; 2) Alphaviruses, such as Sindbis virus and Chickungunya virus; and 3) 
Bunyaviruses, such as Rift Valley Fever virus (RVFV) and LaCrosse virus (LACV). 
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Interestingly, all arthropod viruses that are medically relevant to human health are 
enveloped RNA viruses (140).  
 
2. Bunyaviruses and their replication 
 Bunyaviruses are spherical, enveloped viruses, containing a tripartite negative 
sense RNA genome. Within the virion, the genome bound by nucleocapsid (N) protein, 
and the viral RNA dependent RNA polymerase (RdRp) L is also encapsidated (Figure 
1.1). The viral envelope contains the glycoproteins, Gn and Gc, responsible for entry 
(15, 113). In addition to these 4 proteins, bunyaviruses encode up to three nonstructural 
proteins that are dispensable for infection in cell culture and are virulence factors (15, 
54, 133). 
 The bunyaviral genome consists of three segments, Large (L), Medium (M) and 
Small (S). The L segment encodes the viral RdRp (L), while the S segment encodes the 
N protein and the non-structural NSs protein; some bunyaviruses (including RVFV) 
encode their S segment genes in an ambisense fashion. The M segment encodes one 
polyprotein that is processed into the glycoproteins (Gn and Gc), and depending on the 
bunyavirus species there may also be up to two nonstructural protein (NSm1 and NSm2) 
that are also processed through differential cleavage (Figure 1.1) (15). 
As obligate intracellular parasites with a limited coding capacity, viruses must 
utilize existing cellular pathways for their replication. Arboviruses in particular replicate in 
disparate and evolutionarily distant hosts; as such, arboviruses provide a unique system 
to probe deeply conserved cellular biological processes. Bunyaviral replication has 5 
main steps: 1) entry; 2) mRNA transcription; 3) protein translation; 4) genomic RNA 
replication; and 5) egress (Figure 1.2). Bunyaviruses bind to largely unknown receptors 
and enter through endocytic pathways. Some are thought to enter through clathrin-
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mediated endocytosis, while for others macropinocytosis has been shown to be 
important. Uncoating and viral fusion with the membrane are pH dependent and require 
endosomal acidification (45), but the exact requirements and pathways for bunyaviral 
entry are poorly understood (80). Following entry, the viral genome is transcribed in the 
cytosol by N and L into viral mRNA through a mechanism known as “cap-snatching,” 
detailed below in Section 1.3. Transciptional termination is determined by a short (5-6 nt) 
motif, and bunyaviral mRNAs are largely not polyadenylated (8). Some bunyaviral 
mRNAs have been shown to have stem-loop structures at their 3’ ends that facilitate 
translation and are thought to be similar to the stem-loop structure required for 
replicating histone mRNA translation. However, this structure is not present in all 
segments, which makes it unclear how those mRNAs are translated (8, 12). 
Interestingly, translation of viral mRNAs occurs co-transcriptionally, whereby 
translational elongation prevents premature mRNA transcriptional termination (7). 
mRNAs synthesized from the S and L segments are translated on cytoplasmic 
ribosomes, while M segment mRNA is translated by ribosomes associated with the 
rough endoplasmic reticulum; M segment derived proteins mature in the golgi (55). 
Genome replication occurs through the transcription of an antisense cRNA intermediate, 
from which the genome is amplified. Genomic replication is thought to occur on Golgi 
derived tube-like membrane invaginations (48). Following genome encapsidation by N, 
assembly occurs at the golgi membrane, potentially through interactions between N and 
the intracellular terminus of Gn or Gc (55). Virions bud into the golgi, where they utilize 
the cell’s secretory pathway for release via exocytosis. 
 
3. Cap-snatching as a mechanism of viral mRNA transcription 
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 Eukaryotic mRNAs recruit ribosomes for translation and enhance their stability 
using two structures: a 5’ cap encoded by a methylated guanosine attached in a 5’ to 5’ 
orientation via a triphosphate bond, and a 3’ polyadenosine tail. All viruses utilize host 
ribosomes for translation and thus must recruit host ribosomes. Viruses that transcribe 
their mRNA in the nucleus, such as Human Immunodeficiency virus (HIV), hijack the 
cellular capping and polyadenylation pathways to make their mRNAs indistinguishable 
from endogenous messages. Cytoplasmically replicating viruses have evolved diverse 
mechanisms to recruit host ribosomes and to protect their 5’ and 3’ RNA ends from 
degradation. First, some cytoplasmically replicating RNA viruses, such as Sindbis virus 
(SINV) and Vesicular Stomatitis virus (VSV), use their RdRps to cap and polyadenylate 
their mRNAs (2, 74). Second, some viruses, including the arthropod-transmitted 
flaviviruses, lack poly-A tails, but use nonstructural proteins to create 5’ caps and recruit 
ribosomes through use of internal ribosome entry sites (IRES), sequences that form 
elaborate secondary structure to facilitate ribosome assembly (124). Third, negative 
sense segmented RNA viruses have all evolved a mechanism of ‘cap-snatching,’ in 
which the 5’ cap and a short sequence of a host mRNA is cleaved by the viral RdRp and 
used as a primer to initiate transcription of viral mRNAs (50). 
 Segmented negative sense RNA viruses include the orthomyxoviruses, the 
arenaviruses and the bunyaviruses. Best studied of these are the orthomyxoviruses, in 
particular Influenza A virus, primarily due to its drastic impact on human health. 
Orthomyxoviruses transcribe their mRNA in the nucleus and cap-snatch off of pre-
mRNAs that are not fully spliced (59, 102). Unlike Influenza, bunyaviruses and 
arenaviruses transcribe their mRNAs in the cytoplasm and thus they must use a distinct 
pool of host mRNAs. Bunyaviruses recognize 5’ caps of host mRNAs using specific 
binding sites on the N protein, and their polymerase encodes endonuclease activity that 
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cleaves 10-18 nt downstream of the 5’ cap (17, 85, 100, 106, 116). This primer is then 
used to initiate viral mRNA transcription (Figure 1.3). Therefore all bunyaviral mRNAs 
have 10-18 nucleotides (nt) of nonviral origin at their 5’ end (116). The pool of 
endogenous mRNAs that are snatched by bunyaviruses is not known; however data 
from Mir et al. demonstrated that ectopically expressed mRNAs incorporate into viral 
mRNAs, and that this incorporation is increased if a nonsense-mediated decay (NMD) 
signal is introduced into the mRNA (83). This suggests that bunyaviral cap-snatching 
may interact with the host RNA decay machinery, but it is unknown how this may occur. 
 
4. Rift Valley Fever virus 
 Bunyaviruses are a large diverse group that is divided into 5 genera: rodent-
transmitted hantaviruses (the only genus lacking an arthropod vector); plant-infecting 
tospoviruses transmitted by thrips; tick-transmitted nairoviruses; mosquito-transmitted 
orthobunyaviruses (e.g. La Crosse virus); and the phleboviruses, which are primarily 
transmitted by biting flies, but some of which (e.g. Rift Valley Fever virus) are mosquito-
transmitted (135). In the orthobunyavirus genus, La Crosse virus is endemic to the 
United States and can cause severe pathology in the young, elderly and immune 
susceptible, including encephalitis and death (52, 56). Hantaviruses, which are the only 
genus of bunyaviruses transmitted through aerosolization of rodent exceta rather than 
biting arthrpods, are highly fatal and cause severe pulmonary pathology in infected 
humans; recent outbreaks of the hantavirus Sin Nombre virus in the United States have 
caused fatalities (1). The emerging phlebovirus, Rift Valley Fever virus (RVFV) is 
considered a select agent by the USDA and Human Health and Services and has been 
considered to be a bioterrorist threat (140). RVFV typically causes self-limiting febrile 
illness in humans, but it can cause fatal hemorrhagic or encephalitic disease in 1-3% of 
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patients and has high mortality rates among livestock (13, 101). Unlike most other 
viruses in the phlebovirus genus, which are tick-transmitted, RVFV is transmitted by 
mosquitoes. RVFV is endemic in Africa but has recently spread to the Arabian peninsula 
(47); mosquito species elsewhere, including in the US, have been shown to be capable 
of carrying and transmitting RVFV, highlighting the importance of this pathogen to 
human health, both worldwide and domestically (47). Additionally, the natural vertebrate 
reservoir of RVFV is unknown. Infection of humans occurs either by the bite of a 
mosquito or through the handling of infected livestock (47). There are no commercially 
available vaccines or specific treatments for RVFV. This is due in part to our lack of 
understanding about the interplay between this virus and cellular host factors. 
 
5. RNAi screening as a method to identify host-pathogen interactions 
The advent of technology allowing for the artificial use of the RNA-interfence 
(RNAi) pathway to target specific messages has opened the door for new approaches to 
loss of function screening. High-throughput cell based screening technology has led to 
an explosion of unbiased RNAi screening to identify host factors that pathogens subvert 
or hijack. In addition to allowing for the identification of novel therapeutic targets, these 
studies have also led to a greater understanding of cellular biology, including basic 
cellular mechanisms of viral recognition and limiting factors for viral replication (29). 
Drosophila provides an excellent model for unbiased RNAi screening for 
conserved host factors impacting viral pathogens (34, 58, 88, 107, 108, 112). In addition 
to their high efficiency of RNAi knockdown, their limited genomic redundancy as 
compared to mammals allows for a greater chance of identifying potential targets based 
on a single gene knockdown approach. Additionally, in tissue culture, there is no need to 
transfect to perform RNAi on Drosophila cells, decreasing the rate of knockdown 
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variability and cost. Using Drosophila as a model also allows for ease in transitioning to 
in vivo approaches for confirmation of screen hits, as comprehensive mutant and in vivo 
RNAi lines are commercially available and have short generation time (27, 28, 33). 
Technically, the long-term use of fruit flies as a model has also led to an exceptionally 
well-annotated genome, and almost complete genomic coverage can be obtained 
commercially for RNAi screening. Finally, Drosophila has been shown to share 
conserved immune factors and pathways with higher organisms, including humans (e.g. 
Toll) (72), and thus provides an excellent model for probing conserved interactions with 
viral pathogens. 
 
6. RNA degradation 
 The steady-state levels of RNAs are driven by two competing pathways: 
biogenesis and decay. In Eukaryotes, mRNA stability and translation are intricately 
linked by both cis and trans elements. At the 5’ end, the RNA cap protects against 5’ to 
3’ decay by exonucleases and promotes translation. Likewise, at the 3’ end, the polyA 
tail recruits Poly A Binding Protein (PABP), which prevents 3' to 5’ decay and promotes 
translation (127). Furthermore, proteins bound to these elements promote RNA 
circularization, which also facilitates translation initiation. Therefore, to degrade an 
mRNA, these protective elements must be removed. Deadenylation is thought to be the 
initial signal triggering most RNA turnover and is thought to be proceeded by or 
concomitant to decreases in the rate of translation. Subsequently, RNAs can be 
degraded from either end. The RNA exosome is a large complex that includes two 
exonucleases and is the major 3’ to 5’ exonuclease in the cell. 5’ to 3’ decay first 
requires the removal of the 5’ cap, and this step is rate limiting for decay. mRNA 
decapping occurs on aberrant pools of mRNAs in the nucleus, as well as on 
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deadenylated mRNAs in the cytoplasm. Canonical mRNA decapping itself is catalyzed 
by the NUDIX domain of DCP2, which cleaves the RNA cap, leaving an RNA moiety with 
a 5’ monophosphate. This 5’ monophosphate is the substrate for processive degradation 
by the 5’ to 3’ exonuclease XRN1 (Figure 1.4) (91). Recently, increasing complexity in 
decapping has been described in mammals with the identification of NUDT16, another 
NUDIX domain containing decapping enzyme with widespread tissue expression in mice 
and humans (118). Initial reports suggest that these decappers have both redundant and 
specific functions in specialized RNA decay pathways, such as RNA silencing, NMD 
decay and AU-rich-element (ARE) mediated decay (76). Furthermore, activators of 
decapping have been identified, including the human DEAD box RNA helicase 
DDX6/Rck. Many of these proteins are RNA binding and inhibit translation; as translation 
and decapping are competing steps, these activators tip the balance in favor of decay 
(35, 46, 122). However, the exact mechanisms of decapping activation are unknown (94, 
142). 
 
7. Processing bodies 
 Processing (P) bodies are recently described (43) cytoplasmic aggregates of 
RNPs that contain most of the RNA decay machinery. These RNP complexes are 
endogenously present and are dynamically regulated; microscopically visible P bodies 
fluctuate with various cellular stresses and conditions (42). P body granules are thought 
to contain all of the RNA silencing, non-sense mediated decay and 5’ to 3’ RNA 
degradation machinery (64, 114, 129). Unlike closely related stress granules, ribosomes 
are absent from P body complexes (41). Changes in P body architecture have been 
described following knockdown or overexpression of various components (42). Further, 
visible punctae integrity is dependent not only on particular nucleating proteins, but also 
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on the endogenous RNAs in these complexes (42). Interestingly, while silencing and 
decapping components are in P bodies, the presence of microscopically visible punctae 
is not required for their activity (42). This suggests that while P body architecture may be 
informative, it is not be physiologically required for some cellular activities occuring in P 
bodies (42). Furthermore, some RNAs are thought to be stored in these structures, and 
RNAs targeted to P bodies sometimes re-enter pools of translating mRNAs (4, 99). For 
example, specialized cell types, including germ cells and neurons, have P body-like 
structures that share many protein components with P bodies (97, 141). These RNP 
granules are thought to be sites of mRNA storage and to allow for the control of mRNA 
translation in a spatially and temporally regulated manner. Increasing electron 
microscopy evidence also suggests that P bodies and specialized P body structures are 
in close proximity with ribosomes (36, 141), although whether this close association 
facilitates the return of P body mRNAs to translational pools or is the result of incoming 
mRNAs being targeted for degradation is not clear. 
 
8. Aim of present studies 
Rift Valley Fever virus has shown the potential to spread as it has emerged; 
originally isolated to Sub-Saharan Africa, RVFV has spread to cause outbreaks in Egypt 
and the Saudi Arabian Peninsula in the last few decades. As mosquitoes throughout the 
United States are permissive to infection, and since its impacts on human health and 
livestock could be catastrophic, increasing our understanding of the molecular 
mechanisms of RVFV replication is essential to the development of therapeutics and 
vaccine strategies. Therefore, the work described in Chapter III aims to characterize the 
host-pathogen interactions of RVFV using a cell-based genome-wide RNAi screen in 
Drosophila. The goal of these studies is to identify host-pathogen interactions, especially 
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those that may be conserved among multiple hosts of RVFV infection, for potential 
therapeutic intervention. 
From the genome-wide RNAi screen in Chapter III, I found that three 
components of the P-body-resident RNA decapping pathway were antiviral in 
Drosophila. In Chapter III, I go on to characterize the mechanism by which the RNA 
decapping enzyme Dcp2 restricts RVFV replication and find that this restriction is 
bunyaviral specific and occurs at the level of cap-snatching. I demonstrate that RNA 
decapping and cap-snatching are competing processes for the same pool of RNA 
substrates, and that cap-snatching and decapping are spatially linked in P bodies. Using 
sequencing strategies to examine the 5’ ends of viral mRNAs, I find that cap-snatching 
occurs primarily on cell cycle related mRNAs in insects. In Chapter III, I also show that P 
body morphology and the cell cycle are linked in insects, extending the findings of others 
in humans to show that this is a deeply conserved process. 
I next extended these studies to examine whether cap-snatching is a conserved 
bottleneck for RVFV infection in humans. In Chapter IV, I demonstrate that either of the 
characterized mRNA decappers in humans, DCP2 or NUDT16, is able to restrict RVFV 
infection. Additionally in Chapter IV, I set out to characterize the pools of endogenous 
mRNAs that are snatched by RVFV in humans; I find that RNAs related to translation are 
predominantly snatched during infection and demonstrate both redundancy and 
specificity of the decapping enzymes to degrade these RNA targets. Intriguingly, in 
Chapter IV, I find that RVFV infection triggers loss of microscopically visible P bodies in 
humans late in infection, which may be due to the activation of decapping as an antiviral 
response to RVFV. Thus, these studies demonstrate that mRNA decapping has a deeply 
conserved intersection with bunyaviral replication and provide insight into potential 
therapeutic targets for bunyaviral treatment in multiple host organisms. 
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Figure 1.1. Rift Valley Fever virus virion structure and coding strategy. Rift Valley Fever 
virus virions are enveloped (dark red) and spherical and composed of four main structural 
proteins: the glycoproteins Gc (orange) and Gn (peach) on the envelope surface, the 
nucleocapsid (N) protein encapsidating the anti-sense viral genome (dark red circles), and the 
viral polymerase (L), which facilitates viral transcription following viral entry (bright red wedges). 
The viral genome is comprised of three anti-sense segments: Large (L), encoding the viral 
polymerase; M, which encodes two nonstructural proteins (NSm1 and NSm2) and the 
glycoproteins (Gn and Gc); and S, which encodes the nonstructural virulence factor NSs and the 
nucleocapside protein N in an ambisense strategy.
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Figure 1.2. Bunyaviral entry, replication and assembly. Bunyaviruses enter cells by first 
binding to largely unknown receptors (top left) that mediate endocytosis. Entry occurs in a pH 
dependent fashion. Viral mRNA transcription occurs via a cap-snatching mechanism (middle left). 
Viral mRNAs encoding the glycoproteins Gn and Gc are translated by ribosomes into the rough 
endoplasmic reticulum (middle); these proteins then mature in the golgi. Other viral proteins are 
translated in the cytoplasm and facilitate viral genomic replication (bottom left to right). Viral 
genome is encapsidated by nucleocapsid protein and buds into the golgi (middle right). Finally, 
fully assembled virions egress from the cell using cellular exocytosis pathways (top right).  
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Figure 1.3. Bunyaviral cap-snatching. Host mRNA caps (blue) are recognized by the viral 
nucleocapsid protein, which recruits the viral polymerase L. L cleaves 10-18nt downstream of the 
5’ cap, yielding a snatched, capped oligomer and an RNA moiety with a 5’ monophosphate. L 
transcribes the viral mRNA from the genomic RNA downstream of this primer. Completed viral 
mRNAs have host derived 5’caps (blue) and lack poly-A tails; some viral mRNAs may have 3’ 
stem-loops that aid in viral translation (red).  
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Figure 1.4. 5’ to 3’ mRNA decay in Eukaryotes. To initiate 5’ to 3’ RNA decay, cellular mRNAs 
are deadenylated and then targeted to the canonical decapping enzyme, Dcp2, which resides in 
Processing (P) bodies. Dcp2 cleaves the 5’ to 5’ triphosphate bond, removing the 7mG cap and 
exposing a 5’ monophosphate. This monophosphate is the substrate for the processive 5’ to 3’ 
exonuclease XRN1. 
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II. MATERIALS AND METHODS 
 
1. Cells, Viruses, Antibodies and Reagents 
 Drosophila DL1 cells were grown and maintained as previously described (32). 
Human U2OS cells were grown and maintained as previously described (88). VSV-
eGFP (gift from J. Rose) was grown in BHK cells as described (105). Sindbis/GFP (gift 
from R. Hardy) was grown in C636 cells (21). DCV was grown and purified as described 
(32). MP12 strain of RVFV was grown in Vero cells as described (45). Original strain of 
LACV was prepared as described previously (66). Antibodies were obtained from the 
following sources: anti-GFP (Invitrogen), anti-tubulin (Sigma), anti-DCV (32), anti-RVFV 
N ID8 and anti-RVFV Gn 4D4 (gifts from R. Doms), anti-Rck (MBL), anti-Dcp1a 
(Abcam), anti-beta Integrin (Abcam), and Alexa-488 conjugated Rabbit anti-Flag 
(Invitrogen). Fluorescent secondary antibodies were obtained from Invitrogen, and HRP-
conjugated antibodies were obtained from Amersham. Additional chemicals were 
obtained from Sigma. 
 
2. RNAi  
dsRNAs were generated as described (18). For RNAi, DL1 or Aag2 cells were 
passaged into serum free media and plated into wells containing dsRNA. One hour later, 
complete media was added and cells were incubated for three days.  
 
3. siRNA 
 U2OS cells were seeded on 6 well plates in 2mL complete DMEM, then 
transfected with the indicated siRNA using HiPerfect transfection reagent in OptiMEM at 
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a final concentration of 20nM. Cells were incubated for three days to allow for 
knockdown. 
 
4. Viral Infections 
 Insects: Three days post-RNAi, cells were infected with the indicated viral 
inoculum. VSV (MOI=0.01) and DCV (MOI=0.4) were processed at 24 hours post 
infection. SIN (MOI=2.5) and RVFV (DL1-MOI=0.01, Aag-2-MOI=0.06) were 
spinoculated at 1200 rpm for 2 hours and processed at 36 hours and 30 hours post-
infection, respectively. For RNA collection, cells were infected with either RVFV 
(MOI=0.1) or LACV (MOI=2.5), spinoculated for 2 hours at 1200rpm, and collected at 
either 30 or 72 hours, respectively. 
 Human cells: Three days post-siRNA cells were infected with RVFV at an MOI of 
1. Cells were processed at 18-22 hours post infection for all experiments unless 
otherwise indicated. 
 
5. Immunofluorescence 
 Cells were fixed, processed, imaged by automated microscopy and subject to 
automated image analysis as described (107). For colocalization studies, z-stacks of 20 
planes were taken at 63X, deconvolved and scored. 
 
6. RNA analysis 
 Total RNA was extracted, northern blotted and quantified as previously described 
(30). RT-qPCR was performed as previously described (143). Primer sequences are 
described below in section 2.13. 
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7. Cycloheximide treatment 
 Drosophila cells were treated with the indicated dsRNA and infected with RVFV. 
28 hours post infection, cells were treated with 10µg/mL cycloheximide, and total RNA 
was collected every 30 minutes. 
 
8. 5’RACE and cloning 
5’RACE was performed using the FirstChoice RLM-RACE kit from Ambion 
according to the manufacturer’s instruction. RT-PCR was performed as described (143) 
using primers specific for the 5’RACE adaptor (forward) and RVFV N transcript (reverse) 
and gel purified (Qiagen) prior to ligation using TOPO TA cloning system (Invitrogen). 
Sequences were blasted against the Drosophila genome; those that matched within 40 
bp of the annotated 5’ end of a transcript and containing less than or equal to 1 end 
mismatch were considered hits. 
 
9. BOWTIE analysis of human 5’RACE sequences 
 Snatched sequences were mapped to the Hg19 genome with BOWTIE, using a 
seed length of 12 and allowing zero mismatches. The resulting regions were intersected 
with the coordinates of annotated human 5' UTRs, downloaded from UCSC (Hg19). The 
5' UTRs were then manually inspected to verify the presence of the snatched sequence 
near the transcriptional start site. If multiple matches were present, distance from the 
annotated transcriptional start site was used to determine the more likely match. 
 
10. Exonuclease Digest Assay 
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10µg of total RNA was denatured at 95ºC for 2’, then either mock treated or 
digested using Terminator Exonuclease (Epicentre) as per manufacturer’s instruction 
and evaluated by northern blot. 
 
11. Adult Fly Infections 
 Flies were obtained from the VDRC or Bloomington stock center. 4-7 day old flies 
carrying UAS-Dcp2 IR (VDRC transformant: 22272) or control (w1118) were crossed to 
hs-Gal4 and challenged and heat shocked every two days (RVFV) or maintained at 29°C 
throughout the experiment (LACV) (32). Flies were monitored daily for mortality 
(analyzed with a log rank test) or 15 flies per condition were processed at the indicated 
time point post infection for RNA analysis as described (143). 
 
12. Cap radiolabeling of mRNA 
 Uncapped mRNA was in vitro transcribed from pT GFP vector (83) using a T7 
transcription system (Ambion T7 5x Megascript Kit) and then purified by precipitation. 
RNA was capped using Vaccinia Virus Capping System (NEB) with P32 alpha-GTP 
(Perkin Elmer) according to manufacturer’s instruction.  
 
13. Oligonucleotide Sequences for Probes and RT-PCR 
 
Dcp2 qPCR primers (Drosophila):  
F 5’- CGCAAGGAGAAGCAGCAACAACTT-3’,  
R 5’- TGACTGGCTGCTGTGGATTGTACT-3’ 
 
DDX6 qPCR primers (Drosophila): 
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F 5’- TCGATTTCCCACGAATGGCAGAGA-3’,  
R 5’- TCCGATGCAGATCAAACCGATCCT-3’ 
 
CG8878 qPCR primers (Drosophila):  
F 5’- AGGCGCTATGAAGGTAAACCCACT-3',  
R 5’- TATGCTCCTGGACAACCAAACCCT-3’ 
 
CG7580 qPCR primers (Drosophila):  
F 5’- TCCAACGTCTTCATCGTTACTC-3',  
R 5’- TTATTCGTCGTTCGCGTAGTC-3’ 
 
Jupiter qPCR primers (Drosophila):  
F 5’- GCTACAAGGTCGTAGCCAAC-3',  
R 5’-ACAGGCCCGACGAGTAG-3’ 
 
RP49 qPCR primers (Drosophila):  
F 5’-AAGAAGCGCACCAAGCACTTCATC-3’,  
R 5’-TCTGTTGTCGATACCCTTGGGCTT-3’ 
 
Dcp2 dsRNA primers (Drosophila):  
F 5’-TAATACGACTCACTATAGGAGACCGGGTTCGATATCAC-3’,  
R 5’- TAATACGACTCACTATAGGTCCCGCTCCCGTTCCA-3’ 
 
DDX6 dsRNA primers (Drosophila):  
F 5’- TAATACGACTCACTATAGGCACTCCCGGACGAATATTAG-3’,  
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R 5’- TAATACGACTCACTATAGGAGATTGCGACAGAGTCCTT-3’ 
 
Dcp2 dsRNA primers (Aedes):  
F 5’- TAATACGACTCACTATAGGCAAACTGTCGGTTCCCACTT-3’,  
R 5’- TAATACGACTCACTATAGGGCCATTCCTTTCTGTTTGGA-3’ 
 
DDX6 dsRNA primers (Aedes):  
F 5’- TAATACGACTCACTATAGGCAGTACTACGCGTTCGTCCA-3’,  
R 5’- TAATACGACTCACTATAGGGGCCAATTCTGTGCAGGTAG-3’ 
 
DCP2 qPCR primers (Human): 
F 5’- TCCTCGAGAGGTGGAGAAA-3’ 
R 5’- GAGAGCCACAGCTTCAGTATAA-3’ 
 
NUDT16 qPCR primers (Human): 
F 5’- GGTAGGCAGCCACTATCATTT-3’ 
R 5’- GCAGTCCCTGCAGCTATATT-3’ 
 
GAPDH qPCR primers (Human): 
F 5’- ACCAAATCCGTTGACTCCGACCTT-3’ 
R 5’- TCGACAGTCAGCCGCATCTTCTTT-3’ 
 
5’RACE primers: 
 
5’RACE adaptor outer primer:  
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F 5’-GCTGATGGCGATGAATGAACACTG-3’ 
 
5’RACE adaptor inner primer: F  
5’-CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG-3’ 
 
Host mRNA-viral mRNA conjugate RT-qPCR primers: 
 
MP12 N R: 5’-GGGCTTGTTGCCACGAGTTAGA-3’ 
 
MP12 N F: 5’-CAAGCAGTGGACCGCAATGAGA-3’ 
 
Drosophila His3 5’end Forward primer (with T7 linker):  
5’- TAATACGACTCACTATAGGATTGTGTTTTC-3’ 
 
Drosophila CG8878 5’end Forward primer (with T7 linker):  
5’- TAATACGACTCACTATAGGAAAAACTGCGTG  -3’ 
 
Drosophila Jupiter 5’end Forward primer (with T7 linker):  
5’-TAATACGACTCACTATAGGTTTAGCGGCTTAC-3’ 
 
Human HIS3 5’end Forward primer (with T7 linker): 
5’- TAATACGACTCACTATAGGCTATGGCACG -3’ 
 
Human H2A 5’end Forward primer (with T7 linker): 
5’- TAATACGACTCACTATAGGATGTCNGGACG-3’ 
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Human RPS3A 5’end Forward primer (with T7 linker):  
5’-TAATACGACTCACTATAGGTCTGACCAGCACC-3’ 
 
Human RPL37A 5’end Forward primer (with T7 linker):  
5’-TAATACGACTCACTATAGGCTTTCTGGGCTC-3’ 
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III. MRNA DECAPPING RESTRICTS BUNYAVIRAL REPLICATION BY LIMITING 
THE POOLS OF DCP2-ACCESSIBLE TARGETS FOR CAP-SNATCHING IN 
INSECTS1 
 
1. Background  
RNA stability is a key factor in the regulation of eukaryotic gene expression. 
Within the RNA moiety, cis elements, including the 5’ 7mG cap and the 3’ poly-A tail, 
play dual roles in protecting the mRNA from exonuclease-mediated degradation and 
promoting translation. RNA degradation is both actively regulated and an essential part 
of normal RNA turnover (127). Two strategies account for the majority of mRNA 
turnover: 3’ to 5’ mediated decay via the exosome and 5’ to 3’ degradation by the 
exonuclease Xrn1. Both strategies are dependent on loss of protective cis elements; 
initial deadenylation of the polyA tail signals for both exosome-dependent targeting and 
removal of the 5’ 7mG cap by the canonical decapping enzyme Dcp2 (127). Dcp2 
cleavage of the cap exposes a 5’ monophosphate that is the substrate for Xrn1 (90). 
Furthermore, perhaps as a regulatory mechanism, the RNA degradation machinery is 
largely compartmentalized within the cytoplasm. The decapping machinery and the 5’ to 
3’ exonuclease are localized to Processing (P) bodies (64, 115, 129). P bodies are 
granules of ribonucleoproteins (RNPs), microscopically visible, and are dynamic in their 
size and number. Additionally, P bodies act as storage depots; some RNAs targeted to 
the P body are degraded, while others may be released (99). Thus the dynamic control 
of mRNA stability and turnover can be regulated by P body biology. This is consistent 
with the fact that cellular conditions, including stress and translational inhibition, alter the 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  This chapter is reprinted from Hopkins, K., L. McLane, T. Maqbool, B. Gordesky-Gold, and S. 
Cherry. 2013. A genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral 
replication by limiting the pools of Dcp2-accessible targets for cap-snatching, Genes & 
Development, with permission from Cold Spring Harbor Laboratory Press. 
24 
visible morphology of P bodies within the cytoplasm (42). Interestingly, however, 
microscopically visible P body punctae are dispensable for the function of multiple 
mRNA decay pathways, suggesting that their structure is a marker for increased pools of 
accumulating mRNAs (42). 
As obligate intracellular pathogens with limited coding capacity, viral RNAs must 
replicate to high levels and hijack the translation apparatus, while simultaneously 
avoiding the host’s degradation machinery. Furthermore, RNA viruses must also 
maintain stability of different RNA species, including the genome, antigenome and 
mRNA. Viruses have evolved complex strategies to protect their 5’ ends from 
exonucleases while facilitating translation. Some viruses that replicate in the nucleus 
hijack the endogenous capping machinery (e.g., retroviruses), while viruses that 
replicate in the cytoplasm cannot. To overcome this barrier, some cytoplasmic viruses 
encode their own capping machinery and generate mRNAs that resemble endogenous 
mRNAs (e.g., rhabdoviruses) (73). Other viruses protect the 5’ end from degradation by 
covalently attaching a protein to the 5’ end that prevents targeting by exonucleases (e.g., 
picornaviruses). However, this prevents canonical translation, and thus these viruses 
use internal ribosome entry sites to engage the translation machinery (110). Another 
group of viruses “cap-snatch,” that is they steal the 5’ end of host mRNAs using a virally-
encoded endonuclease, generating primers that are used by the viral RNA-dependent 
RNA polymerase to generate viral mRNAs (51). The 5’ end of the viral mRNA is 
therefore indistinguishable from endogenous mRNAs, and thus it is both protected from 
degradation and able to recruit host ribosomes.  All negative sense segmented RNA 
viruses (orthomyxoviruses, arenaviruses and bunyaviruses) cap-snatch. Of these, 
Influenza A virus, an orthomyxovirus, is the best studied and snatches the 5’ end of pre-
mRNAs in the nucleus (59, 102). Since bunyaviruses and arenaviruses replicate in the 
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cytoplasm, they must use a distinct pool of mRNAs; however, while our mechanistic 
understanding of bunyaviral cap-snatching is increasing (25, 85, 87, 106, 130, 131), little 
is known about whether the host can combat this replication step or what pool of 
endogenous mRNAs are being targeted for this process. 
Bunyaviruses are an emerging group of medically and agriculturally important 
viruses, many of which are insect-borne. Rift Valley Fever virus (RVFV) is a mosquito-
borne emerging bunyavirus in Africa that can cause encephalitic or hemorrhagic 
symptoms in infected humans, leads to spontaneous miscarriage in pregnant livestock 
and causes high rates of mortality in young animals (13, 101). Currently there are no 
therapeutics or FDA approved vaccines to combat bunyaviral infection. This is in part 
due to a lack of understanding of the molecular interactions occurring between 
bunyaviruses and host cells. We set out to identify host factors that restrict RVFV 
infection in insects using Drosophila as our model insect due to the ease of genetic 
manipulation both in vitro and in vivo. RNAi in Drosophila cells is robust, and conserved 
immune biology with humans has been demonstrated (e.g., Toll)(72), suggesting that we 
can use Drosophila to probe both insect and human antiviral factors (26, 58, 88, 107, 
108, 112). Furthermore, Drosophila has been used as a model to study arboviral 
infection, including RVFV (45, 88, 93, 107, 108, 112). 
 Using genome-wide RNAi screening in Drosophila cells, we identified 131 genes 
that impact RVFV (strain MP12) infection, including Dcp2, the P body resident mRNA 
decapping enzyme. Dcp2 restricts RVFV in Drosophila and mosquito cells and also in 
adult flies. This restriction is likely general to bunyaviruses, since the distantly related 
bunyavirus La Crosse virus is also restricted by Dcp2. Mechanistically, we found that the 
viral nucleocapsid (N) is localized to P bodies, and RVFV competes with the RNA 
degradation machinery for target mRNAs. Increasing the pool of mRNAs targeted for 
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degradation via the depletion of Dcp2 or cell cycle arrest in late S/early G2 led to 
increased RVFV replication, while decreasing targets via ectopic expression of Dcp2 
restricted infection. Therefore, our data point to a model in which the pool of Dcp2-
accessible mRNAs is dynamically regulated and presents a bottleneck for RVFV 
replication. 
 
2. Results 
 
Genome-wide screening implicates the mRNA decapping machinery as a 
restriction factor for RVFV 
In order to identify host factors that restrict RVFV, we performed a high-content 
genome-wide RNAi screen in Drosophila cells. Briefly, 384-well plates were arrayed with 
dsRNAs targeting approximately 13,000 genes in the Drosophila genome (Ambion); 
Drosophila cells were seeded and knockdown was allowed to proceed for three days. 
Cells were then infected with the MP12 strain of RVFV (MOI= 0.25) (23), which differs by 
only 11 amino acids from the wild type strain ZH548, making it likely that cellular factors 
that impact MP12 replication will also impact wild type strains (134). 30 hours post 
infection (hpi), cells were stained for total nuclei and RVFV nucleocapsid (N). Automated 
microscopy, followed by automated image analysis was used to calculate the average 
percent infection per well (RVFV N positive cells/total cells) from four sites per well, and 
the screen was performed in duplicate. Genes with a Robust Z-score ≥1.3 or ≤-1.3 in 
duplicate (p<0.05) that were non-toxic (Robust Z-score ≥-2 in duplicate) were considered 
hits (Figure 3.1A). 179 genes were identified, amongst which 56 were part of multi-
subunit complexes (e.g., ribosome, proteasome). Therefore, we chose only 1 or 2 genes 
per complex to verify as a representative, leaving 143 genes to validate. We generated 
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independent dsRNAs targeting unique regions of 143 genes from the initial set and 
validated 85 genes. Including the genes identified in the primary screen that were 
validated by another member of their complex, this comes to 131 genes. 124 genes 
restricted infection while 7 promoted infection (Figure 3.1B, 3.2, Table 6.1). In addition, 
Gene Ontology (GO) enrichment analysis indicated that these candidates were 
significantly enriched for genes involved in DNA replication, the cell cycle and mRNA 
metabolic processes (Figure 3.1C). Importantly, our gene list was also enriched for 
genes conserved with humans and mosquitoes; 124 were conserved with mosquitoes 
and humans, 4 were conserved in mosquitoes, while only 3 did not have identified 
orthologs in these groups. This suggests that the factors and pathways identified may 
have conserved interactions with RVFV replication across multiple relevant hosts. 
Additionally, we validated three genes that reside in P bodies (115): the 
canonical mRNA decapping enzyme Dcp2, LSM7 (part of the heptameric LSM1-7 
complex that participates in decapping activation) (95) and the Drosophila homolog of 
human DDX6/Rck/p54 (Me31B), which has been characterized as an activator of 
decapping in yeast (35, 46), although its mechanism is unclear (94, 122, 142) (Figure 
3.1B, 3.2, 3.3A-C, 3.4, Table 6.1). P body components participate in multiple mRNA 
degradation pathways, including silencing and decapping (40), and P body morphology 
can be altered by the loss of specific P body components. Loss of Dcp2 leads to 
increased P body size, while the loss of DDX6 leads to the dispersal of P bodies in 
Drosophila (data not shown, and (42)). Furthermore, visible P bodies are not necessarily 
required for functional activity of P body resident proteins, including RNA silencing, 
nonsense mediated decay and mRNA decay (42). Therefore, we set out to elucidate 
whether P bodies themselves or particular functions within P bodies, such as decapping, 
were specifically involved in RVFV restriction. We screened 7 other canonical P body 
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resident proteins, including HPat (Patr-1), GW182 (gw), Dcp1 (a binding partner for 
Dcp2), EDC4 (Ge-1), staufen (stau), LSM14A (tral, not part of the LSM1-7 complex) and 
EDC3, and found that none of them impacted RVFV replication greater than 2-fold, 
although loss of LSM14A or EDC3 led to modest, but significantly increased levels of 
RVFV infection (Figure 3.3C). Interestingly, LSM14A and EDC3 are mRNA decapping 
activators in yeast (95) and are required for DDX6 recruitment to P bodies in Drosophila 
(125), suggesting their effects may be through this mechanism. Our data suggest that 
while RVFV replication is restricted by mRNA decapping (Dcp2 and four decapping 
activators), P body integrity is not essential for this restriction or for RVFV replication. 
 
Dcp2 restricts the bunyavirus RVFV but not other families of RNA viruses 
In order to determine the specificity of this restriction, we tested whether Dcp2 
impacts the replication of RNA viruses from three disparate families: Drosophila C virus 
(DCV), Sindbis virus (SINV) and Vesicular stomatitis virus (VSV). DCV is a positive 
sense RNA picorna-like virus and natural pathogen of Drosophila (32, 67). DCV does not 
use a 5’ cap for translation but rather couples a protein to the 5’ end for protection and 
uses internal ribosome entry sites for translation (110). SINV is a human arbovirus that is 
a positive sense RNA alphavirus, and VSV is an arbovirus that is a negative sense 
single stranded RNA rhabdovirus; both of these viruses encode their own 5’ capping 
machinery (2, 73). We found that Dcp2 specifically restricts RVFV, since depletion of 
Dcp2 has no impact on the level of infection by DCV, SINV or VSV (Figure 3.3B). Since 
the only known role for Dcp2 is in decapping, and it selectively restricted RVFV, we 
hypothesized that decapping per se specifically limits RVFV replication through this 
biological function. 
 
29 
RVFV N associates with P bodies 
Since we identified P body resident proteins as antiviral against RVFV, we tested 
whether the viral replication machinery and P bodies interact during RVFV infection. 
Previous studies of the distantly related bunyavirus Sin Nombre virus found that the 
nucleocapsid protein (N), necessary for cap-snatching, forms visible punctae in 
mammalian cells that colocalize with the P body resident protein DCP1a (83). We 
generated cells expressing Dcp1-GFP, which labels P bodies (42), and infected them 
with RVFV for 30 hours. Analysis of these cells demonstrated that N punctae partially 
overlapped with P body punctae (Figure 3.5A). More than half of the infected cells 
presented with at least one colocalization (Figure 3.5B). Furthermore, the majority of 
these events presented with partial overlap rather than complete colocalization (only 3 
colocalizations were found to be coincident), resembling previous reports showing that P 
bodies may contain distinct compartments (111, 141). Additionally, colocalization studies 
examining P bodies and the Ty3 retrotransposon in yeast have shown similar patterns of 
partial overlap (9). Since Dcp2, but not Dcp1, is antiviral (Figure 3.3C), we next 
examined whether Dcp2 colocalized with RVFV N. We generated cells expressing myc-
Dcp2 (65) and infected them with RVFV for 30 hours. We found that coincident 
colocalization occurred in ~90% of infected cells (Figure 3.3D, E), while only a small 
subset of cells showed instances of partial overlap between RVFV N and Dcp2 punctae 
(~2%). Interestingly, when we co-expressed Dcp1-GFP and myc-Dcp2, we saw a 
spectrum of overlap where the large majority of punctae had substantial overlap of Dcp1 
and Dcp2, while others showed partial overlap or no overlap (Figure 3.5C). This 
suggests complexity to these compartments. Taken together, our data suggest that 
RVFV, and perhaps bunyaviruses in general, interacts with P bodies or P body resident 
proteins. 
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Dcp2 restricts bunyavirus infection in adult flies 
 We set out to determine the role of Dcp2 in antiviral defense against RVFV at the 
organismal level in adult flies (45). Arboviral infection of the insect host is controlled by 
the innate immune system. If compromised, an otherwise non-lethal infection can 
become pathogenic and potentially fatal (108, 132, 136). Since Dcp2 is an essential 
gene (79, 103), we used in vivo RNAi technology to deplete Dcp2 post-developmentally 
in adult flies to determine the impact of the decapping machinery on RVFV replication. 
Briefly, transgenic flies bearing a UAS element driving the expression of an inverted 
repeat (IR) against Dcp2 were crossed to flies expressing the Gal4 protein under the 
control of a heat shock inducible promoter. Adult flies were subjected to heat shock, 
driving expression of the snap-back transgene and mRNA depletion, which had no 
impact on survival (Figure 3.5A, B). As expected, control flies infected with RVFV 
presented with little mortality; however, Dcp2-depleted flies succumbed to RVFV 
infection (Figure 3.6A). This increase in mortality was accompanied by increased levels 
of viral replication as measured by northern blot at 6 days post infection (Figure 3.6B, C). 
We also examined viral RNA levels at 20 days post infection, when flies are dying from 
infection, and found that while we see less of an increase in Dcp2 depleted flies 
compared to day 6, increased replication continues late into infection (Figure 3.7C, D). 
We hypothesize that the differences we see are greater at day 6 due to highly infected 
flies in the population succumbing to infection by day 20 post infection. Additionally, we 
tested whether decapping restricted another distantly related bunyavirus, La Crosse 
virus (LACV), an orthobunyavirus transmitted by mosquitoes to humans (53, 57). Control 
flies challenged with LACV presented with little mortality, while Dcp2-depleted flies 
succumbed to LACV infection (Figure 3.6D). Additionally, we found increased viral RNA 
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levels in flies infected with LACV as measured by quantitative RT-PCR 6 days post 
infection (Figure 3.7E). Thus, Dcp2 restricts bunyaviruses both in cell culture and in vivo 
in adult flies. 
 
Decapping restricts RVFV in Aedes aegypti mosquito cells 
RVFV is unusual among arboviruses in that it has been isolated in nature from a 
large number of mosquito species, and numerous mosquitoes can experimentally 
transmit this virus, including Aedes aegypti, the major vector for Dengue virus (128). 
Since there are no cell lines available for many of the more common vector mosquitoes 
that transmit RVFV, and their genomes have not been sequenced, we took advantage of 
the fact that Aedes aegypti is a sequenced vector mosquito. Aag-2 cells, derived from 
these mosquitoes, are permissive to RVFV and amenable to robust RNAi (Figure 3.6E) 
(22, 89).  There are two annotated Dcp2 orthologs in the Aedes aegypti genome 
(AAEL015607 and AAEL000783) with 99% amino acid sequence identity, allowing us to 
design a single dsRNA targeting a conserved region of both Dcp2 genes to deplete both 
simultaneously. Aag-2 cells were subject to RNAi using the same method as with 
Drosophila cells. Three days post RNAi cells were challenged with RVFV (MOI of 0.06) 
for 24 hours, fixed and stained for total nuclei (blue) and RVFV N protein (green). 
Automated microscopy and automated image analysis revealed a significant increase in 
the percentage of RVFV infected Dcp2-depleted mosquito cells (Figure 3.6E, F), 
suggesting that decapping is a conserved mechanism of bunyaviral restriction among 
insects. 
 
Dcp2 does not restrict RVFV by directly decapping viral mRNAs 
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 One major difference between the replication strategies of segmented negative 
sense viruses (RVFV, LACV) and non-segmented negative sense viruses (VSV) is the 
mechanism by which they cap their viral mRNAs. While VSV encodes its own 5’ capping 
machinery (VSV L) (73), RVFV does not.  Rather, all segmented negative sense RNA 
viruses (bunyaviruses, arenaviruses and orthomyxoviruses) “cap-snatch” the 5’ ends of 
host mRNAs, simultaneously defending the 5’ end of their mRNAs from exonucleases 
and facilitating translation. Bunyavirus encoded nucleocapsid (N) protein specifically 
binds the 5’ caps of host mRNAs (85). The viral RNA-dependent RNA polymerase (L), 
which has endonucleolytic activity (100, 106), then cleaves host mRNAs 10-18 
nucleotides downstream of the 5’ cap and uses this primer as a template for viral mRNA 
transcription (17, 100, 116). Thus, all viral mRNAs from this family (RVFV encodes 4 
mRNAs (Figure 3.8)) begin with a short sequence of nucleotides of non-viral origin. 
 We reasoned that if Dcp2 restricts RVFV replication at the step of cap-snatching, 
there are 3 likely mechanisms: 1) Dcp2 may be restricting the pool of available host 
mRNAs through normal metabolic turnover (indirect mechanism); 2) following cleavage 
by the viral L protein, short host-derived primers may be decapped prior to viral RNA 
transcriptional elongation; 3) Dcp2 may be directly decapping host mRNA-viral mRNA 
conjugates following or concomitant to viral transcription (direct mechanism). The 
second mechanism is highly unlikely; following cap-binding and cleavage the 5’ cap is 
bound by viral proteins and thus likely occluded from Dcp2 recognition (84), and in 
yeast, Dcp2 has been shown to be largely inactive on mRNAs <30bp (120). 
In order to clarify which of the other mechanisms restricts RVFV, we took two 
approaches: we first assayed the cap status of viral mRNAs in the presence or absence 
of Dcp2, and second, we examined the decay rate of viral mRNA species in the 
presence or absence of Dcp2. First, we developed an assay to distinguish capped 
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mRNAs from those that have been decapped by Dcp2, which leaves a 5’ 
monophosphate on mRNAs following cap cleavage (90). Terminator Exonuclease 
degrades 5’-monophosphate bearing RNAs, including those which are the product of 
Dcp2-mediated decapping. Cellular 28S rRNA, which natively has a 5’ monophosphate, 
was completely digested by this enzyme (Figure 3.9A, B), while the capped mRNA 
dRPS6 remains largely intact (95% protected, Figure 3.9A, C, D). We also analyzed the 
level of background digestion that occurs in this assay by radiolabeling the cap of GFP 
mRNA transcribed in vitro and then subjecting these capped mRNAs to digestion in the 
presence or absence of cellular mRNA, as this is the context of our experimental 
samples. We found that without cellular RNA, ~18 percent of the GFP signal was lost in 
digested samples compared to mock controls. Interestingly, this level of digestion was 
reduced to ~12 percent with the addition of cellular RNA, presumably due to the 
abundance of rRNA competing for digestion (Figure 3.10A).  
If Dcp2 were directly decapping viral mRNAs post cap-snatching, loss of Dcp2 
would increase the proportion of undigested viral mRNA (capped) present in the viral 
RNA pool. Conversely, if Dcp2 were decapping the mRNA substrates available for RVFV 
to snatch from, there would be no change in the relative proportion of mRNA that was 
digested, even though there would be an increase in overall viral mRNA levels. 
Since the N and NSs mRNAs are significantly different in size from their genomic 
segment, this allows us to distinguish them from the S genomic RNA. In contrast, the 
other viral mRNAs are not sufficiently different in size from the genomic RNA to 
distinguish by northern blot (Figure 3.8). Thus, we chose to examine the N transcript 
since it is essential; NSs is dispensable for replication in cell culture (14). We found that 
~75% of the viral N mRNA was protected from digestion in control cells, presumably by a 
5’ cap (Figure 3.9F); accounting for background levels of digestion, this suggests that 
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anywhere from 13-25% of the viral mRNA is uncapped natively. Moreover, we observed 
that Dcp2 knockdown leads to an overall increase in viral N mRNA levels (Figure 3.9A, 
E); however, Dcp2 knockdown did not significantly alter the proportion of protected N 
mRNA (Figure 3.9A, F). This suggests that Dcp2 does not directly decap viral mRNAs. 
Furthermore, we found that Dcp2 does not seem to regulate the steady-state levels of 
the housekeeping mRNA dRPS6, as there is no change in dRPS6 mRNA in the 
presence or absence of Dcp2, with or without digestion (Figure 3.9A, C, D). These 
findings suggest that Dcp2 restricts the RNA substrates available for RVFV-mediated 
cap-snatching and does not globally affect the cap status of mRNAs within the cell. This 
is consistent with the finding that Dcp2 does not globally regulate mRNA turnover, but 
impacts the stability of only small subsets of mRNAs from yeast to humans (75, 77, 146). 
Furthermore, depletion of the P body resident 5’ to 3’ exonuclease Xrn1, does not impact 
viral infection levels, N transcript levels, or digestion assay results, suggesting that viral 
mRNAs themselves are not under considerable pressure from the 5’ to 3’ degradation 
pathway (Figure 3.10 B, C, D).  
Since there was a degree of background digestion occurring with the 
exonuclease assay, we set out to directly determine whether Dcp2 impacted viral mRNA 
stability. Unlike cellular mRNAs, whose decay can be measured by treatment with 
Actinomycin D and subsequent monitoring for loss of mRNA, viral RNA dependent RNA 
polymerases are refractory to Actinomycin D preventing the use of this approach. 
However, a unique feature of bunyaviruses is that transcription of mRNAs is coupled to 
translation (7); therefore, treatment with cycloheximide (CHX), which inhibits 
translational elongation, prevents viral mRNA transcription, allowing us to examine the 
rate of viral mRNA decay. 
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For these studies, we infected dsRNA treated Drosophila cells with RVFV for 28 
hours, and then treated cells with CHX. We collected total RNA every 30 minutes and 
examined viral mRNA levels via northern blot (Figure 3.9G). RVFV N mRNA has a half-
life of ~30 minutes (Figure 3.9H). Furthermore, RVFV N mRNA decayed at the same 
rate in Dcp2-depleted and control cells (luciferase) (Figure 3.9H), suggesting that Dcp2 
is not affecting viral mRNA stability. Furthermore, we observed no changes in viral 
genome levels over time with CHX treatment in the presence or absence of Dcp2, 
indicating that short-term disruption of translation does not globally impact the stability of 
other RNA species (Figure 3.9I). Altogether, these data suggest that Dcp2 is not directly 
decapping viral mRNAs, but rather decaps specific pools of mRNA that are the 
preferential targets of RVFV cap-snatching.  
 
RVFV selectively snatches cell cycle related mRNAs 
As our results suggest that Dcp2 and RVFV compete for the same pool of mRNA 
targets, we set out to determine which mRNAs were being snatched. This may also 
reveal the particular mRNAs that are regulated by Dcp2-dependent decapping. Thus, we 
performed 5’ RNA ligase mediated (RLM)-RACE and sequenced the 5’ ends of viral N 
mRNA transcripts from RVFV infected Drosophila cells. Of the 40 sequenced reads, we 
were able to align 33 to the 5’ end of endogenous RNAs (Figure 3.11A, 3.8). Of these 
33, we found 4 instances in which we found the same gene being snatched in 
independent experiments, leaving 29 independent genes. There were no obvious 
consensus sequence motifs within this gene set, suggesting that if there are structural or 
sequence specific motifs targeted by Dcp2, they are not contained within the first 15 
nucleotides. We found that while 9 of the 29 genes had no annotated GO terms, half of 
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the remaining 20 genes (10) had terms associated with the cell cycle and mitosis (Figure 
3.11A, 3.12).  
To determine whether the stability of these target mRNAs is impacted by Dcp2, 
we performed RNAi in Drosophila cells and assayed host mRNA levels by quantitative 
RT-PCR. We found that indeed, mRNA levels for three genes tested (CG8878, CG7580 
and Jupiter) were increased upon Dcp2 depletion (Figure 3.11B). To determine if these 
genes were used as a target for RVFV snatching, we used a forward primer containing 
the first 11bp of either CG8878 or Jupiter, in addition to another gene identified, Histone 
3 (His3), a replication-dependent histone, and a reverse primer in the N transcript. Using 
this assay, we found that the viral Host-N fusion mRNAs were increased upon Dcp2 
knockdown as compared to control (Figure 3.11D). These data suggest that Dcp2 
affects RVFV replication primarily by restricting the substrate mRNAs available for cap-
snatching, and that cell cycle mRNAs are targeted both by decapping and cap-
snatching. 
 
P body morphology is regulated by the cell cycle 
Interestingly, previous studies in human HeLa cells suggested the rapid turnover 
of replicating histone mRNAs (such as His3) at the end of S phase is dependent on 
Dcp2 (92, 121). This observation, along with our identification of a large number of cell 
cycle related mRNAs as targets of RVFV-dependent cap-snatching, suggests that cell 
cycle related mRNAs are degraded by Dcp2 in Drosophila. Emerging data also suggest 
that P bodies are regulated by a number of different biological inputs, including the cell 
cycle. P body size and number increase as mammalian cells exit S phase and enter G2 
(145). This may be due to the influx of mRNAs encoding DNA replication machinery and 
histones that need to be degraded, and this accumulation may result in increased 
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granule assembly leading to increased P body size. We examined whether P body size 
or number was influenced by the cell cycle in Drosophila. We used RNAi against cyclins 
to arrest the cells in G1 (CycD knockdown) or late S/G2 (CycA knockdown) (11). As 
expected, we observed an increase in nuclei size upon S/G2 arrest (Figure 3.11E). This 
was concomitant with a significant increase in P body area and number (Figure 3.11F, 
G), suggesting that cell cycle dependent regulation of P bodies is deeply conserved, and 
that P body size during the cell cycle may serve as a marker for the load of mRNAs 
destined for degradation. 
 
Cell cycle arrest in late S/early G2 enhances RVFV replication  
Since P body size is regulated by the cell cycle with the apex at late S/early G2, 
which is likely due to increased targeting of RNAs for degradation, and mRNA target 
levels are seemingly a bottleneck for RVFV replication, we hypothesized that RVFV may 
replicate most efficiently when P bodies are at their largest and P body mRNAs are in 
high abundance. Indeed, analysis of our validated RNAi screen gene set revealed 39 
genes that had the GO term “cell cycle” and were antiviral (Figure 3.1C, 3.2). 
Furthermore, the entire DNA replication factor A complex (RPA2, RpA-70 and 
CG15220), whose depletion results in S phase arrest, was also antiviral in our screen 
(Figure 3.2, Table 6.1). Moreover, we found that 28 genes impacted the cell cycle 
arresting at S/G2, as measured by increased nuclear area upon depletion (Figure 3.2, 
Table 6.1), of which 26 genes were antiviral and 15 genes did not have an annotated 
GO term associated or literature reference to the cell cycle, suggesting that they may 
have a previously unknown role in the cell cycle. To validate this, we performed RNAi 
against a panel of genes that arrest the cell cycle at specific stages. Treatment of cells 
with dsRNA to arrest in S/G2 (CycA, cdc2, RnRs) led to increased levels of infection, 
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while arrest in G1 (CycD, cdc2c, CycE) had no impact (Figure 3.13A, B), consistent with 
the fact that in log phase, >80 percent of Drosophila cells are in G1 (18). Furthermore, 
we observed increases in RVFV mRNA upon loss of CycA, but not CycD, as measured 
by northern blot (Figure 3.13C, 3.14A), along with increased His3-N mRNA accumulation 
(Figure 3.13D). To determine whether this was specific for RVFV infection, we 
challenged arrested cells with VSV. We found that VSV replication was unaffected by 
S/G2 arrest, while G1 arrest by cdc2 modestly promoted infection (Figure 3.13B). 
Altogether, this data suggests that cell cycle arrest in late S/early G2 is advantageous for 
RVFV replication, and this enhancement is specific to bunyaviruses. 
 
Diverse bunyaviruses are restricted by similar mechanisms in cells 
Our finding that Dcp2 restricts LACV in adult flies prompted us to test this in cell 
culture. Depletion of Dcp2 in Drosophila cells led to increased levels of LACV replication 
as measured by viral RNA levels; similar results were seen with DDX6 depletion (Figure 
3.13E, 3.14B). Next, we tested if LACV, like RVFV, also replicated more efficiently in late 
S/early G2, a time when Dcp2-targeted mRNAs should be abundant. Indeed, we found 
that S/G2 arrest led to increased LACV RNA replication (Figure 3.13E, 3.14B). These 
data suggest that cap-snatching is a bottleneck in the bunyaviral life cycle and that 
modulation of target mRNA levels impacts the replication of diverse bunyaviruses. 
 
Dcp2 is limiting: ectopic expression restricts RVFV replication 
Since loss of Dcp2 leads to increased replication, we hypothesized that enforced 
expression of Dcp2 may restrict RVFV replication by decapping, and thereby limiting, the 
pool of available mRNAs. First, we confirmed that RNAi against Dcp2 substantially 
depleted myc-Dcp2 in our Dcp2 expressing cells by immunoblot (Figure 3.15A). Next, 
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wild type or Dcp2-expressing cells were infected with RVFV, and immunoblot analysis of 
RVFV glycoprotein (RVFV Gn) revealed that Dcp2 knockdown increases RVFV infection 
(Figure 3.15A), consistent with our findings measured by microscopy (Figure 3.3A) or 
northern blot (Figure 3.9E). Additionally, we found that ectopic Dcp2 expression 
significantly restricted RVFV infection as measured by both immunoblot (Figure 3.15A) 
and by microscopy (Figure 3.15B). Furthermore, Dcp2 knockdown restored infection in 
ectopically Dcp2-expressing cells to wild-type levels (compare to luciferase treated 
infected cells (Figure 3.15A, B). These treatments had no effect on VSV infection (Figure 
3.15C), demonstrating specificity. Therefore, Dcp2 levels define a set point for RVFV 
infection. 
 
3. Discussion 
Our genome-wide RNAi screen identified and validated a large number of genes 
that restrict RVFV replication. Amongst this gene set was the canonical mRNA 
decapping enzyme Dcp2 and two decapping activators. The interactions between mRNA 
decay and viral infection are an area of burgeoning study (38, 49, 86); however, there is 
little known about the intersection of the RNA degradation machinery and bunyaviral 
infection, and so we explored this biology. Future studies will reveal the mechanistic 
roles the other validated factors play in viral infection. We focused on Dcp2, which 
specifically restricts the replication of two diverse bunyaviruses (RVFV and LACV) but 
not other RNA viruses, in insects both in vitro and in vivo. Bunyaviruses, unlike the other 
RNA viruses tested, use cap-snatching to generate the 5’ end of viral mRNAs. This is in 
part mediated by the bunyaviral N protein, which binds to 5’ capped mRNAs (85). This 
led us to postulate that RVFV cap-snatching competes with decapping, and suggests a 
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model in which the availability of mRNA substrates is rate limiting for RVFV infection. 
Thus, modulation of these targets can create or eliminate a bottleneck in viral replication. 
Indeed, we find that Dcp2 does not directly decap viral transcripts after snatching 
and transcription have occurred, as knockdown does not impact the cap status of viral 
mRNAs (Figure 3.9F) or their stability (Figure 3.9G, H), and furthermore, that Xrn1 
knockdown does not increase viral mRNA stability (Figure 3.10B, C, D). Rather, mRNA 
decapping during normal RNA turnover keeps the pool of available mRNA targets from 
which bunyaviruses can snatch at a low level. Thus, loss of the decapping enzyme Dcp2 
leads to increased bunyaviral replication, and ectopic expression of Dcp2 restricts 
infection. Furthermore, we found that many mRNA targets that are snatched and 
incorporated into viral transcripts are cell cycle related. Indeed, mRNA levels in P bodies 
are cyclically altered in phase with the cell cycle. As cells transit into late S/early G2, P 
bodies enlarge to accommodate mRNA degradation of mRNAs required for DNA 
replication, and these cells support higher levels of bunyaviral replication. Our genome-
wide RNAi screen identified a large number of cell cycle genes, including all three 
subunits of the DNA replication factor A complex, that arrest the cell cycle at this time as 
antiviral. Interestingly, however, we find that P body dispersion through knockdown of 
components known to be required for P body integrity does not affect RVFV replication; 
this is consistent with data showing that microscopically visible P bodies are not required 
per se for P body associated functions, such as miRNA silencing and NMD decay. 
Indeed, our data strengthen previous findings that P body morphology may be a marker 
for the accumulation of mRNAs destined for degradation within the cell.  
We found that by modulating the pool of host mRNAs targeted for decapping, 
either through changes in the expression level of Dcp2, or by arresting cells in late 
S/early G2 phase, bunyavirus replication is affected in insects. Interestingly, mRNAs 
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carrying nonsense mediated decay signals were incorporated at an increased rate into 
Sin Nombre transcripts in human cells, and Sin Nombre N localizes with P bodies (83). 
This suggests potential conservation of decapping as antiviral against bunyaviruses in 
mammals. In further support of this, Dcp2 is inducible by Type I interferons (75, 109). 
While Drosophila only encode one characterized decapping enzyme, a second 
decapping enzyme (NUDT16) has been recently characterized in both mice and humans 
(117), and an additional six nudix domain containing proteins in mice and one in yeast 
have been shown to have various degrees of decapping activity (119). Drosophila 
encodes no NUDT16 ortholog, however it does encode for 14 other nudix domain 
containing proteins, none of which were identified as antiviral in our genome-wide 
screen. Recent studies have identified a novel decapper in bacteria, which do not cap 
their RNA, suggesting that decapping activity is ancient and preceded mRNA capping in 
evolution (119). This may further support a role for decapping in antiviral defense. 
Interestingly, comparisons have revealed that DCP2 and NUDT16 have both redundant 
and specific targets (76), suggesting that in eukaryotes, decapping may be far more 
complex than first thought. 
One interesting question raised by these observations is why bunyaviruses 
transcribe their viral mRNA in an area rife with mRNA degradation machinery. This is 
particularly perplexing when considering the fact that viral RNA transcription is 
dependent on translation, and P bodies are ribosome-free. We have four hypotheses 
that might explain why bunyaviruses use mRNAs destined for degradation as the target 
for cap-snatching. First, these targets are largely present in a spatially concentrated area 
and destined for degradation. Thus, snatching caps from these mRNAs should not 
negatively impact cell viability. Second, cytoplasmically replicating RNA viruses must 
compartmentalize their replication steps in order to enhance efficiency; segregating RNA 
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transcription to these areas (P bodies) may prevent competition between cap-snatching, 
genome replication and viral RNA packaging into virions. Third, microscopy studies 
indicate that P bodies, and perhaps the RNA degradation machinery in general, are 
surrounded by ribosomes (36, 141). Furthermore, recent studies in Drosophila have 
shown that during oogenesis and early egg activation, translation of mRNAs necessary 
for proper axis formation depends upon RNA localization within sub-compartments of P 
body like RNPs (141). RNAs located deep within the P body core are associated with 
decapping activators and are translationally repressed, while those located towards the 
edge of the P body are able to interact with ribosomes associated with the periphery of 
the P body and can initiate translation. This pool of readily available ribosomes may be 
optimal for initiation of translation of viral mRNAs, since bunyaviral mRNA transcriptional 
elongation requires translation to be occurring concomitantly (7). Thus, it is possible that 
these ribosomes serve this function. Finally, we speculate that the 5’ end of the host 
mRNA molecule, once cleaved, may represent an abnormal or ’foreign’ RNA structure to 
the host cell (5’ monophosphate on an RNA with a 3’ polyA tail). While cellular RNA 
molecules exist with 5’ monophosphates, such as rRNA, these RNAs are heavily 
associated with proteins, which may occlude recognition of their 5’ end structure, and 
are not polyadenylated. Snatching in these localized environments may assure that 
mRNAs that are targeted for snatching can be rapidly degraded by the P body resident 
processive exonuclease, Xrn1. Indeed, there may be parallels between bunyaviral 
snatching of Dcp2 targeted pools in the cytoplasm and nuclear pre-mRNAs by 
orthomyxoviruses. Many pre-mRNAs are aberrantly synthesized, and therefore the 
nucleus has surveillance machinery, which includes an Xrn1 homolog Rat1 that targets 
uncapped mRNAs for degradation. Therefore, in both cases the uncapped host mRNA is 
under close surveillance and thus has a very short half-life. 
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Altogether, we have explored the host factor dependencies of RVFV, leading to 
the finding that two diverse bunyaviruses are restricted by mRNA decapping. 
Furthermore, these studies have revealed new aspects of RNA decay and the regulation 
of these compartments; our results indicate that alteration of P body morphology during 
cell cycle progression is a deeply conserved process from insects to mammals (145). 
We also provide evidence that in Drosophila, Dcp2 decaps mRNAs involved in cell cycle 
progression and DNA replication, in addition to previously established roles in regulating 
histone mRNA levels in human cells (92). This suggests that decapping in Drosophila 
more generally targets mRNAs undergoing rapid turnover. RNA profiling studies in 
murine cells depleted of Dcp2 or NUDT16 suggest that in higher organisms the 
decapping of mRNAs is specialized (75). Thus, selective activation of decapping may 
potentially be a viable therapeutic approach to degrade RVFV accessible mRNAs. 
Indeed, Dcp2 is potentially regulated: in yeast, phosphorylation of Dcp2 by Ste20 is 
necessary for Dcp2 recruitment to P bodies (146), and vertebrate Dcp2 has a number of 
conserved uncharacterized phosphorylation sites (62). Further studies will reveal 
whether decapping of specific cargo can be selectively regulated in insects and 
mammals.  
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Figure 3.1. Genome-wide RNAi screen for host factors that impact RVFV in Drosophila. 
(A) Genome-wide RNAi screen pipeline. Cells were plated onto 384 well plates pre-plated with 
dsRNAs targeting the Drosophila genome. Three days later cells were infected with RVFV MP12 
(MOI=0.25) for 30 hours and processed for immunofluorescence (RVFV N, green; nuclei, blue). 
Automated microscopy followed by image analysis was used to calculate Robust Z-scores, which 
are shown for each replicate of the screen. (B) Primary candidates were validated using 
independent dsRNAs; for complexes with multiple candidates represented in the primary pool, a 
selection of genes were validated as representative of the complex. Robust Z-scores from 143 
genes shown with validated genes in blue, genes that did not validate in grey. Dcp2, DDX6 and 
LSM7 are shown in red, green and orange, respectively. (C) GO term enrichment for validated 
genes. 
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Figure 3.2. Validated screen hits assigned to cellular functions based on informatics 
analysis. Human gene names are shown for all orthologs. Genes in red are pro-viral, green are 
antiviral and black are members of large complexes not directly tested in secondary validation. 
Rab5C and SUPT5H were previously validated and are bolded (45, 143). Underlined genes have 
the GO term “cell cycle,” and an asterisk indicates S phase associated genes in the literature.  
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Figure 3.3. Decapping restricts RVFV replication in Drosophila cells. 
(A) Drosophila cells were treated with the indicated dsRNA for 3 days, then infected with RVFV 
(MOI 0.01) and processed for immunofluorescence (RVFV N protein, green; nuclei, blue). (B) 
Cells were treated as in A and infected with the indicated virus. dsRNA targeting each virus was 
used as a positive control (Virus). Quantification of mean fold change in the percentage of cells 
infected with the indicated virus is shown. Blue – Drosophila C Virus (DCV), purple – Sindbis 
virus (SIN), red – Vesicular Stomatitis virus (VSV), green – RVFV (MP12 strain). Mean±SD of ≥3 
independent experiments; **p<0.01.  (C) Cells treated as in A with P body component dsRNAs 
were quantified for the mean fold change in the percentage of RVFV infected cells. Decapping 
activators are indicated, and genes significantly affecting RVFV replication are highlighted in blue. 
Mean±SD of ≥3 independent experiments; *p<0.05. (D) Representative deconvolved plane of a 
Drosophila cell expressing myc-Dcp2 (green) and infected with RVFV for 30 hours (RVFV N red, 
nuclei blue). (E) Quantification of RVFV N and myc-Dcp2 punctae colocalization events per cell 
(>150 cells from 3 independent experiments). The majority of infected cells (~90%) have at least 
one colocalization between Dcp2 and RVFV N. 
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Figure 3.4. Knockdown efficiency of dsRNAs. Quantitative RT-PCR analysis of Dcp2 (A) and 
DDX6 (B) in cells treated with the indicated dsRNA normalized to RP49 levels and shown relative 
to non-targeting control (luciferase). 
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Figure 3.5. Colocalization of Dcp1 with RVFV and Dcp2. (A) Representative deconvolved 
plane of a Drosophila cell expressing Dcp1-GFP (green) and infected with RVFV for 30 hours 
(RVFV N red, total nuclei blue). (B) Quantification of RVFV N and Dcp1-GFP punctae 
colocalization events per cell (>300 cells from 3 independent experiments). The majority of 
infected cells (54.3%) have at least one colocalization between Dcp1 and RVFV N, although they 
are not coincident. (C) Representative deconvolved plane of a Drosophila cell expressing myc-
Dcp2 (red) and Dcp1-GFP (green). Total nuclei stained in blue. The majority of punctae are both 
Dcp2 and Dcp1 positive with partial overlap shown as closed arrows. However there are some 
punctae that are only Dcp1 or Dcp2 positive shown as dotted arrows.  
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Figure 3.6. Dcp2 restricts bunyaviruses in flies and mosquitoes. 
 (A) Adult flies carrying heat shock inducible Gal4 were crossed to flies that inducibly express 
dsRNA against Dcp2 (hs-Gal4>UAS-Dcp2 IR, red) or controls (hs-Gal4>+, blue) were challenged 
with RVFV, and percent survival is graphed as a function of days post infection (dpi). A 
representative of at least three experiments is shown; p<0.001 log rank test. (B) Northern blot 
analysis of RVFV infected control flies and Dcp2-deficient flies probed for RVFV N mRNA or 
dRPS6 (cellular loading control) 6 days post infection. (C) Quantification of 3 experiments as 
shown in B. Mean±SD; *p<0.05.  (D) Flies as described in A were challenged with La Crosse 
virus (LACV). Percent survival is graphed as a function of time. A representative of at least three 
experiments is shown; p<0.001 log rank test. (E) Representative immunofluorescence of Aedes 
aegypti Aag-2 cells treated with the indicated dsRNA and subsequently infected with RVFV. (F) 
Quantification of mean fold change in percent infection with mean±SD shown; **p<0.01. 
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Figure 3.7. Supplemental information for whole animal experiments. (A) Survival of 
uninfected flies of the indicated genotypes. (B) Quantitative RT-PCR analysis of Dcp2 in adult 
heat shocked flies normalized to RP49 levels and shown relative to control flies. (C) Northern blot 
analysis of RVFV infected control flies and Dcp2-deficient flies probed for RVFV N mRNA or 
dRPS6 (cellular loading control) 20 days post infection. (D) Quantification of 3 experiments as 
shown in C. Mean±SD; *p<0.05. (E) Quantitative RT-PCR analysis of LACV N/S RNA levels 
normalized to RP49 in infected flies of the indicated genotypes day 6 post infection. Mean±SD for 
≥3 independent experiments; *p<0.05.  
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Figure 3.8. Schematic of RVFV genomic RNA, mRNA and protein coding strategy. 
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Figure 3.9. Dcp2 does not directly degrade viral mRNA. 
(A) Drosophila cells treated with the indicated dsRNA and infected with RVFV; total RNA was 
either mock treated or digested with Terminator Exonuclease as indicated. Northern blots were  
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Figure 3.9 (cont.): probed for RVFV N mRNA (capped transcript), 28S rRNA (5’ mono-
phosphate bearing control transcript) or the cellular capped dRPS6 mRNA. (B) Quantification of 
28S rRNA as shown in A, normalized to luciferase mock treated. Mean±SD for ≥3 independent 
experiments; *p<0.05. (C) Quantification of RVFV N mRNA in mock digest samples normalized to 
luciferase control. Mean±SD for ≥3 independent experiments; *p<0.05. (D) Ratio of digested 
RVFV N mRNA divided by the mock treated sample, yielding the ratio of mRNA that is refractory 
to digestion. Mean±SD for ≥3 independent experiments; n.s. not significant. (E) Quantification of 
dRPS6 transcript in mock digest samples normalized to luciferase control. Mean±SD for ≥3 
independent experiments; n.s. not significant. (F) Ratio of digested dRPS6 mRNA transcript 
divided by the mock treated sample, yielding the ratio of mRNA that is refractory to digestion. 
Mean±SD for ≥3 independent experiments; n.s. not significant. (G) Drosophila cells were treated 
with the indicated dsRNA and infected with RVFV. 28 hours post infection, cells were treated with 
cycloheximide (CHX), and total RNA was collected at the indicated time post CHX treatment. 
Northern blots were probed for RVFV N mRNA, the S segment genome, and 28S rRNA as a 
loading control. (H) Quantification of RVFV N transcript in CHX treated samples as shown in G. 
Mean±SD for ≥3 independent experiments; no time points were significantly different between 
control and Dcp2-depleted cells. (I) Quantification of RVFV S segment genome in CHX treated 
samples as shown in G. Mean±SD for ≥3 independent experiments; no time points were 
significantly different. 
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Figure 3.10. Additional controls for Figure 3.9. (A) GFP mRNA transcribed in vitro was capped 
with P-32 GTP, and digested or mock treated with terminator exonuclease in the presence or 
absence of Drosophila cellular RNA as indicated. RNA was run under denaturing conditions, 
transferred to a nitrocellulose membrane and radioactivity was quantified using ImageQuant. 
Mean of 2 experiments +/- SD. (B) Drosophila cells were treated with the indicated dsRNA for 3 
days, then infected with RVFV (MOI 0.01) and processed for immunofluorescence. Percent 
infection was quantified and normalized to non-targeting control. Mean±SD of ≥3 independent 
experiments; n.s. = not significant. (C) Quantification of northern blot analysis from Drosophila 
cells treated with the indicated dsRNA and infected with RVFV. Northern blots were probed for 
RVFV N and normalized to 28S rRNA levels. Mean±SD of ≥3 independent experiments; n.s. = 
not significant. (D) DL1 cells were pretreated with the indicated dsRNAs, infected with RVFV and 
subject to the exonuclease assay. Northern blots were quantified and the ratio of digested RVFV 
N mRNA divided by the mock treated sample, yielding the ratio of mRNA that is refractory to 
digestion. Mean±SD for ≥3 independent experiments; n.s. not significant.  
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Figure 3.11. Cell cycle RNAs are an enriched substrate for RVFV cap-snatching. 
(A) Pie chart of annotated GO function of sequences from the 5’ end of RVFV mRNAs mapped to 
Drosophila. (B) Quantitative RT-PCR of levels of indicated target mRNAs, normalized to RP49 as 
a cellular loading control, and shown as fold change over non-targeting dsRNA (luciferase). 
Mean±SD for ≥3 independent experiments; *p<0.05 (C) Schematic representing position of RT-
PCR primers utilized in D. Forward primers recognizing the first 11 nucleotides of the host gene 
5’UTR were used amplify Host-RVFV fusion mRNA, and internal primers were used to amplify 
total RVFV N mRNA. (D) Quantitative RT-PCR of the indicated Host-RVFV N mRNA conjugates, 
normalized to RP49 as a loading control, and shown as fold change over non-targeting dsRNA 
(luciferase). Mean±SD for ≥3 independent experiments; *p<0.05 (E-G) Cells expressing Dcp1-
GFP, to monitor P bodies, were treated with the indicated dsRNA for 3 days, fixed, imaged and 
analyzed using MetaXpress software. Mean±SD for ≥3 independent experiments; n>500 cells; 
*p<0.05. (E) Average nuclear area shown relative to luciferase control. (F) Average Dcp1-GFP 
foci size relative to luciferase control. (G) Average number of Dcp1-GFP foci per cell relative to 
luciferase control. 
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Figure 3.12. Endogenous sequences cap-snatched by RVFV in Drosophila. List of cap-
snatched sequences, their length and corresponding Drosophila gene. GO terms are shown and  
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Figure 3.12 (cont.): color-coded to the pie chart in Figure 3.11A. Genes that were independently 
identified in multiple experiments are filled purple. 
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Figure 3.13. Cell cycle arrest in late S/early G2 phase enhances bunyavirus replication. 
(A) Representative images of DL1 cells treated with the indicated dsRNA, infected with RVFV for 
30 hours, fixed and stained for RVFV N protein (green) and total nuclei (blue). (B) Quantification 
of cells treated with the indicated dsRNA, then infected with either RVFV or VSV for 30 or 24 
hours respectively. Mean±SD for ≥3 experiments shown; *p<0.05. (C) Cells were treated with the 
indicated cell cycle gene dsRNA. Quantification of northern blot analysis of RVFV N mRNA 
normalized to dRPS6 with the mean±SD for ≥3 experiments shown; *p<0.05. (D) Quantitative RT-
PCR for 5’His3-RVFV N fusion mRNA in cells treated for the indicated dsRNA for 3 days, and 
then infected with RVFV for 30 hours. Mean±SD for ≥3 experiments shown; *p<0.05. (E) DL1 
cells treated with the indicated dsRNA and infected with LACV for 72 hours. Quantification of 
northern blot analysis of LACV N mRNA and S segment genome/anti-genome normalized to 
dRPS6 with the mean±SD for ≥3 experiments shown; *p<0.05.  
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Figure 3.14. Representative northern blots as in Figure 3.13. (A) Representative northern blot 
of DL1 cells treated with the indicated dsRNAs and infected with RVFV for 30 hours quantified as 
in Figure 3.13C. (B) Representative northern blot of DL1 cells treated with the indicated dsRNA 
and infected with LACV for 72 hours quantified as in Figure 3.13E. 
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Figure 3.15. Ectopic expression of Dcp2 restricts RVFV replication. 
(A) Control cells or cells expressing myc-Dcp2 were treated with the indicated dsRNA for 3 days, 
infected with RVFV for 30 hours and analyzed by immunoblot. (B) Cells were treated and infected 
as in A, processed for immunofluorescence and quantification of the percent infection with the 
mean±SD for ≥3 experiments shown; *p<0.05.  (C) Cells were treated as described in A and 
infected with VSV for 24 hours. Cells were processed for microscopy and quantification of the 
percent infection with the mean±SD for ≥3 experiments shown; n.s. not significant. 
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IV. THE MRNA DECAPPERS DCP2 AND NUDT16 LIMIT DISTINCT BUNYAVIRAL 
CAP-SNATCHING TARGETS TO RESTRICT INFECTION IN HUMANS  
 
1. Background 
 Bunyaviruses are a genus of negative sense tripartite RNA viruses that infect 
diverse species, including plants and animals, and are largely vectored to vertebrate 
animals by arthropods, typically mosquitoes or ticks (16). Since these viruses have 
evolved to replicate in such disparate hosts, they likely hijack deeply conserved 
biological mechanisms to replicate. Previously, we found that two mosquito-transmitted 
bunyaviruses, the orthobunyavirus LaCrosse virus (LACV) and the phlebovirus Rift 
Valley Fever virus (RVFV), are restricted by the cellular RNA decapping machinery in 
insects (60). In a genome-wide RNAi screen to examine cellular factors impacting RVFV 
replication in Drosophila, we identified the canonical mRNA decapping enzyme, dDCP2, 
and two activators of decapping, Me31B (DDX6/Rck) and dLSM7, as antiviral against 
RVFV. Mechanistically, we found that mRNA decapping restricts the availability of 
cellular mRNA substrates used by these viruses for viral cap-snatching, a unique 
mechanism of viral mRNA transcription in which the 5’ cap and 10-18 nucleotides (nt) of 
a host mRNA are used as an initiating primer for viral mRNA transcription. Moreover, we 
found that cell cycle mRNAs, which are under tight control by the decapping machinery, 
are the preferential targets used by RVFV, explaining the tight bottleneck imposed by 
dDCP2. 
 Since bunyaviruses also cap-snatch in vertebrates, we examined whether 
decapping is a conserved mechanisms of viral restriction in humans. While lower 
organisms from yeast to insects encode only one known decapper, DCP2, decapping is 
more complex in vertebrates (44). At least two mRNA decapping enzymes have 
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decapping activity in mice and humans, DCP2 and NUDT16 (117). DCP2 is the direct 
homolog of yeast and insect DCP2, while there are no clear homologs of NUDT16 in 
Drosophila. Recent studies have suggested that NUDT16 and DCP2 have both 
redundant and specific decapping targets, and they are thought to be downstream of 
specific RNA decay pathways (76). While microarray profiling has identified panels of 
DCP2 and NUDT16 sensitive targets in murine cells (76) and immunoprecipitation of 
human DCP2 has identified some RNA targets (78), the endogenous mRNA targets of 
human NUDT16 and what overlap they may possess with human DCP2 are largely 
unknown. Additionally, it is unclear how targets are differentially targeted to these 
enzymes and whether they share similar mechanisms of activation. 
Since dDCP2 restricts RVFV in insects by decapping RVFV targets, we set out to 
determine if decapping also presents a bottleneck for RVFV replication in human cells. 
Indeed, we find that depletion of either DCP2 or NUDT16 led to increased RVFV 
replication, and enforced expression of either decapper also restricted viral replication. 
Since either loss of function or gain of function impact RVFV infection, these data 
suggest that DCP2 and NUDT16 are limiting in the cell. By sequencing snatched 
endogenous targets, we found that some targets were restricted specifically by either 
DCP2 or NUDT16, while others were restricted by both decappers. This suggests that 
RVFV cap-snatches in a niche where both DCP2 and NUDT16 are present. It is known 
that DCP2 resides in Processing (P) bodies, RNA-protein (RNP) complexes within the 
cytoplasm that contain the majority of RNA decay enzymes, including DCP2 and its 
known activators (44), and we previously showed that dDCP2 and the RVFV cap-
snatching machinery colocalize in the cytoplasm. Minimal data regarding the localization 
of NUDT16 within the cytoplasm exists, and overexpression and endogenous antibodies 
have shown both punctate and diffuse cytoplasmic staining (81, 117). We find that in 
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addition to DCP2, NUDT16 is present in cellular granules indicative of P bodies. This 
indicates that RVFV cap-snatches in P bodies from DCP2 and NUDT16 targets. 
Intriguingly, we also find that RVFV infection leads to a loss of P body granules. This 
suggests that decapping may be activated as an antiviral mechanism to combat 
bunyaviral infection in humans. Overall, our data demonstrate a competition between 
RVFV cap-snatching and the cellular mRNA decapping machinery for the same pool of 
mRNA targets, and that these targets are limiting for viral replication. Furthermore, we 
identified bona fide targets of RVFV cap-snatching in humans, which are highly enriched 
for ribosomal proteins and other translationally related RNAs. Altogether, we 
demonstrate a conserved role for mRNA decapping in RVFV restriction and suggest that 
DCP2 and NUDT16 have both common and unique niches and targets that overlap with 
virally-targeted mRNAs. 
 
2. Results 
 
Multiple mRNA decappers restrict Rift Valley Fever virus in human cells 
 Since arboviruses, including bunyaviruses, replicate in Plants and in Animals 
from insects to humans (16), we set out to determine whether our finding that RVFV is 
restricted by dDCP2, the sole decapper in insects (61), is conserved in humans. We 
performed siRNA knockdown of the known mRNA decappers in humans, DCP2 and 
NUDT16 (118). While we only achieved modest knockdown at the mRNA level as 
measured by RT-qPCR (Figure 4.1A, B), we found that depletion of either DCP2 or 
NUDT16 lead to a significant increase in the relative infection of RVFV in U2OS cells, as 
measured by the percentage of infected cells (~2-fold; Figure 4.1C). DDX6/Rck is a 
known activator of DCP2-dependent decapping (35, 46) and restricts RVFV in insects 
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(61), and thus we also tested whether depletion of this factor impacted infection. Indeed, 
we found, similar to the effects seen with depletion of the decapping enzymes, a two-fold 
increase in the relative percentage of infected cells upon DDX6 depletion (Figure 4.1C). 
These data suggest that mRNA decapping is a broadly conserved pathway that restricts 
RVFV replication from insects to humans. 
 Our previous findings that decapping restricts bunyaviral replication at the level of 
RNA transcription in insects led us to examine whether RNA levels are increased in 
RVFV infected cells depleted of decapping enzymes. We found, similar to 
immunofluorescence studies, that total viral RNA levels are significantly increased upon 
depletion of DCP2 or NUDT16 as measured by RT-qPCR (~2-fold; Figure 4.1D). Since 
RT-qPCR does not distinguish the viral mRNA from the viral genomic RNA, future 
studies will examine the effects of knockdown of decapping enzymes by northern blot, 
as these RNA species can be distinguished based on size. 
 
DCP2 and NUDT16 are limiting in human cells 
 We set out to determine whether ectopic expression of either decapping enzyme 
could inhibit RVFV replication in humans. We established polyclonal stable cell lines 
expressing either Flag-tagged NUDT16 (118) or GFP-tagged DCP2 (126) and compared 
infection to control cells (Figure 4.2A, B). We observed low levels of these decappers 
after selection that was detectable only by an ultra-sensitive Enhanced 
Chemiluminescent (ECL) substrate capable of detecting protein in the low femtogram 
level by immunoblot (Thermo Scientific SuperSignal West Femto Substrate) (Figure 
4.2C, data not shown), suggesting that abundant overexpression of decapping enzymes 
is deleterious in human cells. 
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Despite these low levels of protein expression, we observed significantly reduced 
levels of viral infection upon enforced expression of either DCP2 or NUDT16 compared 
to control cells as measured by multiple assays. First, we found that ectopic expression 
of DCP2 or NUDT16 significantly reduced the percentage of infected cells (Figure 4.2A, 
B). Second, we measured levels of viral glycoprotein, Gn, by immunoblot, and found that 
viral protein was significantly reduced in the presence of low-level enforced expression 
of NUDT16 (Figure 4.2C). Third, we found significantly reduced viral RNA by RT-qPCR 
with enforced NUDT16 expression (Figure 4.2D). This suggests that decapping is a 
highly regulated process, and that decappers are limiting in human cells. Future studies 
will examine the effects of enforced expression of DCP2 on viral protein and RNA. 
 
Histone mRNAs are a conserved cap-snatching target of Rift Valley Fever virus 
 We previously found that RVFV primarily snatches dDCP2 targets, which are 
largely cell-cycle-regulated mRNAs, for mRNA transcription, including replicating histone 
mRNAs (60).  Therefore, we tested whether replicating histone mRNAs (Histone 3 and 
Histone 2A) are an endogenous target of RVFV cap-snatching in human cells. Thus, we 
used a PCR strategy to capture the specific host mRNA snatched by RVFV using with a 
forward primer against the first 11 nucleotides of the 5’UTR of our host gene of interest 
and a reverse primer against the viral N mRNA transcript. Using this strategy, we find 
that the histone mRNAs H2A and HIS3 are both targets of viral cap-snatching (Figure 
4.3A, B). Interestingly, preliminary data show these target mRNAs appear to be 
increased upon depletion of either DCP2 or NUDT16, although NUDT16 appears to 
have a larger impact. Because either decapper impacts the levels of these mRNAs, our 
data suggests redundancy in target specificity between these decapping enzymes. This 
also suggests that decappers are limiting, since each enzyme is unable to fully 
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compensate for the loss of the other in degrading this pool of mRNAs. This also 
demonstrates for the first time that NUDT16 plays a role in the basal turnover of human 
histone mRNAs (92, 121).  
Additionally, we examined whether enforced expression of NUDT16 reduces the 
levels of histone-viral mRNA conjugates. We found that both H2A- and His3-N 
conjugates were significantly reduced by low levels of NUDT16 ectopic expression 
(Figure 4.3C, D), similar to our observation of decreased total viral RNA (Figure 4.2D). 
These data suggest that NUDT16 levels are tightly regulated, and that minor alterations 
in their expression can profoundly affect the pools of transcripts used by bunyaviruses 
for replication. Future studies will examine the effects of enforced expression of DCP2 
on these RNA species. 
 
RVFV primarily snatches translation related mRNAs, and these mRNAs are limited 
by RNA decapping 
  We set out to determine the spectrum of mRNAs snatched by RVFV in human 
cells using 5’RLM-RACE (60). We obtained 83 sequences of non-viral origin from the 5’ 
end of the viral N mRNA transcript (Table 4.1). The mean length of endogenously cap-
snatched sequences was 13.1nt (S.D. +/- 1.35), and sequences ranged in length from 
10-18 nt, consistent with previous reports (17). There was little sequence preference in 
the first 10nt of the snatched sequences, with the exception of a slight preference for a T 
at position 2 (Figure 4.4A). There was a strong preference for the last nucleotide of the 
snatched sequence before the initiation of the viral sequence to be a C or G (Figure 
4.4B), and this was slightly influenced by the length of the sequence; sequences 12 or 
15 nt in length had a strong C preference, while those 13-14 nt in length showed 
increased G preference for a terminal G residue (Figure 4.4C). Thus, there is a strong 
67 
bias for the RVFV polymerase to cleave endogenous host mRNAs following a residue 
that base pairs with three hydrogen bonds. 
 Interestingly, of the 49 sequences we were able to match back to annotated 5’ 
UTRs in the human genome, we found a strong enrichment for genes involved in mRNA 
translation, including RNAs encoding protein components of the ribosome and 
translation initiation and elongation factors (Table 4.1) (Figure 4.4D). This is in contrast 
with our previous findings in insects, where we found that cell cycle related messages 
were preferentially incorporated into RVFV mRNAs (60). This suggests that specific 
cohorts of genes are targeted during viral cap-snatching, and that these RNAs vary 
between hosts. Potentially, these mRNAs may be in niches where cap-snatching and 
RNA degradation overlap; future work will examine basal levels of these transcripts upon 
perturbation of decapping to determine whether decappers are a driving force for 
translational mRNA stability. 
 Of the endogenous targets observed, we examined the incorporation of two 
ribosomal protein mRNAs, RPL37A and RPS3A, into viral mRNA conjugates. Similar to 
histone mRNAs, incorporation of the 5’ end of RPL37A into viral mRNA was increased 
by either DCP2 or NUDT16 depletion, suggesting that this mRNA is redundantly 
degraded by these enzymes, but that in the absence of one, the other decapper is 
unable to compensate (Figure 4.4E). However, we found loss of NUDT16 more 
profoundly impacted incorporation than DCP2, suggesting potential target specificity. In 
contrast to the redundancy on histone mRNAs, we found that RPS3A-viral RNA 
conjugate levels were dramatically increased upon NUDT16 depletion, but were 
unaffected by DCP2 depletion (Figure 4.4F). This suggests that RPS3A is a specific 
target of NUDT16 decapping, and that it is stabilized upon NUDT16 depletion. Further 
studies will examine the basal levels of these targets in uninfected cells depleted of 
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decappers, and whether any of our other endogenously snatched targets are DCP2 
specific in their manner of decay.  
 
Rift Valley Fever virus infection triggers P body loss in human cells 
DCP2 and other RNA decay machinery reside in cytoplasmic P bodies. We found 
that RVFV nucleocapsid protein, N, co-localizes with dDCP2-containing P bodies in 
insect cells, and Mir et al. have demonstrated that the bunyavirus Sin Nombre N protein 
co-localizes with DCP1A-containing P bodies in human cells. Thus, we examined the 
interplay between RVFV N and P bodies in human cells. First, we visualized P bodies as 
a function of time post infection using the P body marker DDX6, which we have also 
shown is a conserved antiviral factor ((60) and Figure 4.1C). Surprisingly, we found that 
by 12 hours post infection, DDX6 positive punctae were lost in infected cells, but not in 
neighboring uninfected cells in the same field (Figure 4.5A, B). Since DDX6, but not 
DCP1A, can be found in related cytoplasmic RNPs called stress granules, we examined 
DCP1A punctae during RVFV infection. We found that DCP1A positive punctae were 
also lost during RVFV infection (Figure 4.5C, D).  
The localization of NUDT16 in the cytoplasm has not been carefully studied; it is 
unclear whether NUDT16 resides in P bodies, where DCP2 and known decapping 
activators are present. Additionally, whether DCP2 and NUDT16 have overlapping 
locations in the cell has not been examined. Due to technical issues, we were unable to 
visualize endogenous DCP2 or NUDT16 localization in the cytoplasm to examine 
whether: 1) these proteins are punctate in P bodies; 2) whether these punctae colocalize 
with RVFV N; and 3) whether any punctae dissociate with RVFV infection. However, 
preliminary studies examining Flag-NUDT16 did show distinct punctate cytoplasmic 
staining, reminiscent of P bodies (Figure 4.5E). Future studies will clarify the localization 
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of Flag-NUDT16 with DCP2 and other known P body markers basally and in the context 
of RVFV infection. 
 
P body depletion is not autophagy dependent 
 One possible mechanism that can potentially account for the loss of P bodies is 
capture and degradation of these RNPs by autophagy (20). Autophagy is a highly 
conserved process in which large materials, such as damaged organelles, are captured 
by a double membrane structure termed an autophagosome, which then fuses with a 
lysosome that releases its lytic enzymes to complete the degradation of its contents (82). 
Stress granules are degraded through autophagy in a conserved manner from yeast to 
humans, and basal levels of P bodies are increased in autophagy deficient yeast (20). 
We set out to determine whether autophagy activation is responsible for the clearance of 
P bodies in RVFV infected cells, as this could explain P body loss. 
 We found that in U2OS cells treated with siRNAs against the essential autophagy 
proteins, ATG5 and ATG7, viral induced clearance of P body punctae was unaffected 
(Figure 4.6A, B). Furthermore, we used ATG5 knockout MEFs, which cannot undergo 
autophagy, and again observed no affect on P body clearance compared to wild type 
MEFs (Figure 4.6C, D). These data demonstrate that RVFV-induced P body clearance is 
independent of autophagy.  
 
3. Discussion 
 Bunyaviruses infect widely disparate organisms from plants to insects to humans. 
We previously found that dDCP2 creates a bottleneck of mRNA substrates for RVFV 
cap-snatching in Drosophila (60). Since RVFV also infects mammals, including humans, 
we set out to explore the role of decapping in RVFV infection in human cells. Recent 
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studies have revealed the increased complexity of mRNA decapping in mammals, and 
unlike yeast and Drosophila, where only one mRNA decapper is known, at least two 
decappers exist in mammals (118). Interestingly, the specificity of these decappers is 
only beginning to be unraveled (76). We found that decapping is a conserved 
mechanism by which cells restrict bunyaviruses. We found that depletion of either DCP2 
or NUDT16 led to increased RVFV replication, demonstrating a lack of redundancy in 
their activity and an inability to fully compensate for loss of one another. This is in line 
with previous data showing that these enzymes may have both redundant and specific 
endogenous targets and functions within specialized RNA decay pathways (76). Indeed, 
we found that RVFV snatching of RPS3A mRNA is increased upon loss of NUDT16 but 
not DCP2, while RPL37A mRNA is increased upon loss of either DCP2 or NUDT16. This 
demonstrates both specific and overlapping dependencies.  
While it was known that DCP2 resides in P bodies from yeast to humans, the 
localization of NUDT16 within the cytoplasm was unknown. We found that these 
decappers reside in the same compartment where RVFV N is targeting mRNAs. 
Preliminary data suggest that in the context of enforced expression, Flag-NUDT16 forms 
cytoplasmic puncta (Figure 4.5E); these may be indicative of P bodies, and further work 
will examine the spatial localization of NUDT16 in relation to other P body components. 
As we and others have previously found that P bodies are not of uniform composition 
(111, 141), even among the binding partners dDCP2 and dDCP1A in insects (61), the 
possibility exists that NUDT16 and DCP2 specificity and redundancy could be explained 
by differential targeting of RNAs to P bodies containing individual or both decappers. 
While mechanistically it is unknown how specific mRNAs are targeted, it is possible that 
decapping activators, which are known to bind RNA, provide some level of specificity. 
These may either bring mRNAs to P bodies in general or perhaps to specific decappers. 
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Since little is known about NUDT16, and it is not conserved in yeast where most 
decapping activators were first identified, it is possible that there exist decapping 
activators that specifically impact NUDT16 function. Future work will examine the 
composition of these compartments to attempt to understand how RNAs are targeted to 
them. Indeed, there may be additional uncharacterized decappers in mammals. A recent 
report by Song et al. using in vitro decapping assays identified six additional NUDIX 
domain containing proteins in mice with decapping activity (119).  
We found that RVFV preferentially cap-snatches mRNAs associated with 
translation and that the decappers restrict the incorporation of these mRNAs into viral 
transcripts. Indeed, we found seven ribosomal protein mRNAs, one translation initiation 
factor and one elongation factor. This suggests that this cohort of functionally related 
mRNAs is coordinately regulated post-transcriptionally by decapping. RNA operons have 
been defined as pools of functionally related genes that are coordinately regulated post-
transcriptionally by sequence specific RNA binding proteins. While some RNA operons 
are well defined (e.g. histone mRNA stability regulated by stem loop binding protein), 
others have only suggestive evidence (69). Intriguingly, some of the best evidence for 
the coordinated regulation of functionally related genes at the level of mRNA stability 
comes from studies of immune-related gene programs. The mammalian RNA binding 
proteins ELAV/Hu and TTP target chemokine and cytokine mRNAs to promote their 
stability, and the half-lives of these RNAs are synchronously altered during immune 
responses (69). Other evidence for functionally coordinated decay operons comes from 
microarray data examining the half-lives of RNA transcripts in yeast; functionally related 
genes, especially those within the same complex, have similar half-lives (137). Indeed, 
one of the complexes demonstrating a high degree coordination in the decay rate of its 
components is the ribosome (137). This suggests that the directed decay of translation 
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related mRNAs is deeply conserved. Overall, these findings imply that decapping 
activation could be a useful tool to regulate RNAs through targeted RNA decay, or that 
inhibition of decapping could dramatically stabilize these programs. 
Our findings that translation related mRNAs are preferentially snatched during 
RVFV infection are intriguing; if cap-snatching and RNA decapping are indeed 
competing processes, this suggests a high level of targeted degradation of these 
translational mRNAs. mRNAs encoding the core translational machinery, such as 
ribosomal proteins, are known to have 5’Terminal Oligopyrimidine (TOP) motifs, 
consisting of cytosine- and uridine-rich stretches greater than 4 bases at the extreme 5’ 
end of the mRNA (5). The translation and polysome occupancy of TOP motif containing 
mRNAs has been shown to be coordinately regulated in response to mTOR inhibition 
(123). We hypothesize that upon RVFV infection, translation related mRNAs are 
specifically targeted for degradation by decapping as a means to restrict translation of 
viral RNAs to combat infection within the cell. Indeed, many known antiviral programs 
shutdown translation (37, 68). PKR inhibits translation through the phosphorylation of 
EIF2A, but its activity is blocked by RVFV (63). IFIT proteins are interferon-induced and 
inhibit translation initiation at multiple steps, however, RVFV does not induce interferon 
efficiently (10). Additionally, as bunyaviruses have evolved an encoded ability to recruit 
ribosomes without the aid of the EIF4F complex and can recruit the 43S pre-initiation 
complex via their nucleocapsid protein (84), this suggests ancient evolutionary pressure 
to find novel means of ribosome recruitment and translation. As these viruses steal 
endogenous caps, which should not stimulate an immune response, the need to develop 
this activity is not obvious. DCP2 is potentially inducible by interferons (109) in humans 
and by poly I:C and lentiviral infection in murine cells (75), Thus, decapping of translation 
mRNAs may potentially be a novel innate immune effector response. Future work will 
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examine whether the stability of these mRNA targets is affected by perturbation of 
decapping basally in uninfected cells, to see if this targeted degradation is indeed 
triggered as a host response to viral infection.  
Since only subtle increases in the levels of decappers are sufficient to attenuate 
RVFV replication, this suggests that decapping activation may be a reasonable 
therapeutic target to restrict bunyaviral infection. The potential to harness decapping as 
an antiviral mechanism or as a tool to control the expression of specific cohorts of genes 
is exciting. As theoretically druggable targets, decapping activation could be a novel 
mechanism for targeted gene regulation in multiple contexts. 	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Figure 4.1. RVFV replication is increased by depletion of human mRNA decapping 
enzymes in U2OS cells. (A) RNA collected from U2OS cells treated with two pooled siRNAs 
targeting DCP2 three days post transfection was analyzed by RT-qPCR for knockdown efficiency. 
Fold change is normalized to GAPDH (n=1). (B) Cells were treated as in A with siRNAs targeting 
NUDT16 and analyzed by RT-qPCR for knockdown efficiency. Fold change is normalized to 
GAPDH (n=1). (C) U2OS cells were treated with the indicated siRNAs and then infected with 
RVFV (strain MP12, MOI=0.4) for 18 hours. Cells were fixed and stained for total nuclei and 
RVFV N protein by immunofluorescence. Automated image analysis was used to determine the 
percentage of infected cells. Relative infection is shown (n=3, *p<0.05). (D) U2OS cells were 
treated with the indicated siRNAs and then infected with RVFV (MOI=1). Total RNA was collected 
20hpi and analyzed by RT-qPCR for RVFV N RNA. Fold change is normalized to GAPDH (n=3, 
*p<0.05).  
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Figure 4.2. mRNA decapping enzymes are limiting for RVFV infection in humans. (A) U2OS 
cells or stable U2OS cell lines overexpressing GFP-tagged DCP2 were infected with RVFV 
(MOI=0.4). Cells were fixed and stained for total nuclei and RVFV N protein by 
immunofluorescence. Automated image analysis was used to determine the percentage of 
infected cells. Relative infection normalized to control cells is shown (n=3, **p<0.01). (Figure 
4.1A, B)  U2OS cells or stable U2OS cell lines overexpressing Flag-tagged NUDT16 were 
infected with RVFV (MOI=0.4). Cells were processed as in A. Relative infection normalized to 
control cells is shown (n=3, **p<0.01). (C) Control cells or cells expressing Flag-tagged NUDT16 
were infected with RVFV (MOI=1) and total protein was collected 20 hpi and analyzed by 
immunoblot. A representative of three experiments is shown. (D) Control cells or cells expressing 
Flag-tagged NUDT16 were infected with RVFV (MOI=1) and total RNA was collected 20 hpi and 
analyzed by RT-qPCR for RVFV N RNA. Fold change is normalized to GAPDH (n=3, **p<0.01).   
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Figure 4.3. Histone mRNAs are incorporated into RVFV RNAs and limited by decapping. 
(A) U2OS cells were treated with the indicated siRNAs and then infected with RVFV (MOI=1). 
Total RNA was collected 20hpi and analyzed by RT-qPCR for RVFV H2A-N mRNA conjugates. 
Fold change is normalized to GAPDH (n=3, *p<0.05). (B) U2OS cells were treated with the 
indicated siRNAs and then infected with RVFV (MOI=1). Total RNA was collected 20hpi and 
analyzed by RT-qPCR for RVFV HIS3-N mRNA conjugates. Fold change is normalized to 
GAPDH (n=3). (C) Control cells or cells expressing Flag-tagged NUDT16 were infected with 
RVFV (MOI=1) and total RNA was collected 20 hpi and analyzed by RT-qPCR for RVFV H2A-N 
mRNA conjugates. Fold change is normalized to GAPDH (n=3, *p<0.05). (D) Control cells or cells 
expressing Flag-tagged NUDT16 were infected with RVFV (MOI=1) and total RNA was collected 
20 hpi and analyzed by RT-qPCR for RVFV HIS3-N mRNA conjugates. Fold change is 
normalized to GAPDH (n=3, **p<0.01).  
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Figure 4.4. Ribosomal and translationally related mRNAs are targeted by both RVFV cap-
snatching and mRNA decapping. (A) LOGO analysis of the first 10 nt of 83 clones showing  
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Figure 4.4 (cont.): sequence preference of RVFV cap-snatching. Preference for a base is shown 
as a function of letter size. (B) LOGO analysis of the last 10 nt of 83 clones showing sequence 
preference of RVFV cap-snatching. Preference for a base is shown as a function of letter size. 
(C) LOGO analysis of 83 full-length sequences showing sequence preference of RVFV cap-
snatching. Preference for a base is shown as a function of letter size. (D) Analysis of enrichment 
of 49 snatched sequences by cellular GO term. Enrichment of functional categories is shown as a 
function of P value. (E) U2OS cells were treated with the indicated siRNAs and then infected with 
RVFV (MOI=1). Total RNA was collected 20hpi and analyzed by RT-qPCR for RVFV RPL37A-N 
mRNA conjugates. Fold change is normalized to GAPDH (n=3, *p<0.05). (F) U2OS cells were 
treated with the indicated siRNAs and then infected with RVFV (MOI=1). Total RNA was collected 
20hpi and analyzed by RT-qPCR for RVFV RPS3A-N mRNA conjugates. Fold change is 
normalized to GAPDH (n=3, *p<0.05).  
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Figure 4.5. RVFV infection triggers loss of Processing bodies in human cells. (A) U2OS 
cells were infected with RVFV (MOI=1) at 14C and virus was allowed to bind for 1 hour; cells  
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Figure 4.5 (cont.): were then washed and incubated at 37C for 11 hours. Cells were fixed and 
stained for Rck/DDX6 (green), RVFV N protein (red) and total nuclei (blue). (B) Quantification of 
Rck punctae in uninfected versus RVFV infected cells as shown in A. (**p<0.01, n=1). (C) U2OS 
cells were treated and infected as in A. Cells were fixed and stained for DCP1a (red), RVFV N 
protein (green) and total nuclei (blue). (D) Quantification of DCP1a punctae in uninfected versus 
RVFV infected cells as shown in C. (**p<0.01, n=1). (E) Flag-NUDT16 expressing U2OS cells 
were processed and stained with Alexa-488 conjugated anti-Flag (green) and for total nuclei 
(blue). A representative image is shown.  
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Figure 4.6. RVFV-dependent P body clearance occurs independent of autophagy. (A) U2OS 
cells were transfected with the indicated siRNAs and infected three days post transfection with 
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Figure 4.6 (cont.): RVFV (MOI=1) at 14C; virus was allowed to bind for 1 hour. Cells were then 
washed and incubated at 37C for 11 hours. Cells were fixed and stained for Rck/DDX6 (green), 
RVFV N protein (red) and total nuclei (blue). (B) Quantification of Rck punctae in uninfected 
versus RVFV infected cells as shown in A. (**p<0.01, n=1). (C) WT or ATG5-/- MEF cells were 
infected with RVFV (MOI=1) at 14C; virus was allowed to bind for 1 hour. Cells were then washed 
and incubated at 37C for 11 hours. Cells were fixed and stained for Rck/DDX6 (green), RVFV N 
protein (red) and total nuclei (blue). (D) Quantification of Rck punctae in uninfected versus RVFV 
infected cells as shown in C. (**p<0.01, n=1).   
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Snatched sequence (5' to 3') Official Gene Symbol 
CTTTCTGGGCTCAC RPL37A 
CTTTTCATTCCC C17orf76-AS1 
TCTGACCAGCACC RPS3A 
CGCCACCGTCGTC KRT8 
CGCGTCGCTAGC NDUFS5 
ACGGCCAGGTTGGGT AGL 
ACTTCCGGTTCCCG MTRF1L 
CTCTTCCGCCGTCAC EEF2 
GTTTTGCAGACGC PPIA 
AAGCGTTGGGTGAC LOC339240 
CTCTGCCACTCTCG TTC28 
CTTTTTCGCA EEF1A1 
TGGCCCCAGCGGTG IWS1 
CTCAGCAGCCAG DDHD2 
TTCTCTCTCGGC EIF3C 
CAGACCGCCGAGG PCBP1 
CTCTCGCCAGGC RPLP0 
GCGGAGCCGCG HDAC1 
CACTCGTGTCTC BEX1 
CTTTTCTCTCTC BET1 
AGTGTGAGGGGC NOMO1 
CTCGGCAGCCGC SNX29 
GGCGCAGAGGCCTGC HBS1L 
CCCCTCTCTGTCTT DESI1 
ACTTGGCTTCAAAGC CDK1 
AGCTGGCCAGGTC LOC541473 
CTCTTTCGCTCAGG RPS23 
GTTTTTCCAAAG DLEU7-AS1 
GTTTCGCCTCAGG DERL1 
TTTCTGCCCGTGGACG HNRNPA1 
AGGAGCGTAGAGGC FAF2 
TTCTGGCGCGGAG MARCKSL1 
AGAGTCCGAGCCG CUL3 
CTCTTTCCAGCCAGC RPS8 
CCCTTTCCTCAGC RPLP1 
AGTGCGGGGTCGGC CTSZ 
GTTTTGCAGACG PPIA 
CGCCTGGACGCAG FXYD5 
AGTAGCAGCAGCG TPRXL 
CTCTTCCGCCGCC RABGGTA 
GCTGCCGCCGTCGC CADM2 
CTCTTTCCCTTC RPL10 
CCCAGACCAGC PCBP2 
ACAAAGCCCAGACG HNRNPM 
AGAGCCGCCATC ARF1 
CTTGGAGAAGCAAG GPR61 
AGCCGCTGCGCCCGAG THBS1 
TTAGCGACTATTGC REXO2 
ACCGACCAAAATGGC ETAA1 
Table 4.1. Cap-snatched sequences mapped back to human 5’UTRs.  
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V. CONCLUDING REMARKS  
 
1. Summary 
 With climate change increasing the natural range of biting-insect vectors and the 
encroachment of human development into the habitat of reservoir species, arboviruses 
are an increasing threat to human health and agriculture worldwide. The lack of antiviral 
therapeutics and vaccines against these pathogens necessitates that we increase our 
understanding of their host requirements and immune evasion in order to combat these 
diseases. Additionally, the unique lifecycle of arboviruses provides an excellent tool to 
probe deeply conserved biological pathways and how these viruses interact to subvert or 
utilize these functions. To this end, we have performed a genome-wide RNAi screen in 
Drosophila cells to understand the virus-host interactions of the mosquito-transmitted 
bunyavirus, Rift Valley Fever virus, and extended these findings to human studies. 
 Our genome-wide RNAi screen identified 131 host factors that impact the 
replication of RVFV (strain MP12) in Drosophila. We found 124 factors that, when 
depleted, allowed for increased infection, including multiple members of the 5’ to 3’ RNA 
decay pathway: dDCP2, the canonical mRNA decapping enzyme, and two known 
activators of decapping, Me31B/DDX6 and dLSM7. Additionally, we identified 7 factors 
whose presence was necessary for efficient viral replication, including Rab5C, which has 
been previously validated as a required factor for bunyaviral entry (45); taken together 
with our previous finding that SUPT5H, another antiviral factor present in our gene set, is 
antiviral against other arboviruses in Drosophila (143), the results of this screen have 
both validated former knowledge of arboviral replication and enriched our understanding 
of RVFV-host interactions in insects. 
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 As viruses have evolved unique mechanisms of hijacking host factors, unusual 
molecular structures have evolved to decoy and recruit host proteins. Concomitantly, 
cells have also evolved ways to detect and destroy these Pathogen Associated 
Molecular Patterns (PAMPs). One such molecular signature are the unusual RNA 
species made during viral infection that are not normally found in cells, especially in the 
case of RNA viruses. A variety of host proteins exist to detect and destroy these unusual 
RNAs throughout distantly related species. The RNAi silencing machinery in particular 
has been shown to be potently antiviral in plants and insects, and some viruses have 
even evolved ways to subvert this pathway. It is possible that other host pathways of 
RNA decay are utilized in an antiviral fashion, in addition to their basal metabolic 
functions within the cell. There has been recent increased interest in the understanding 
of the interaction between viral replication and RNA decay factors. Interactions have 
been demonstrated between 5’ to 3’ decay machinery and mosquito-transmitted 
flaviviruses, such as West Nile virus (WNV) and Dengue virus (DENV). XRN1 and 
DDX6, which we found to be antiviral factors for RVFV replication, have been shown to 
be recruited to viral replication sites and required for efficient WNV replication (24), and 
DDX6 has been shown to bind to DENV viral RNA to facilitate replication (138). These 
data, along with our finding that VSV and SINV replication are not effected by RNA 
decapping, suggest that bunyaviral replication is specifically restricted by the RNA 
decapping machinery. 
 I demonstrated that RNA decapping in insects restricts bunyaviruses indirectly by 
creating a bottleneck of mRNA substrates available for cap-snatching. Rather than 
directly decaying viral RNA species, I found that dDCP2 does not affect viral mRNA cap-
status or stability. Rather, dDCP2 restricts infection through the basal metabolism of its 
own RNA substrates. Immunofluoresence studies revealed that the viral N protein, 
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essential for cap-snatching, colocalizes with dDCP2 to a high degree in cytoplasmic 
punctae. Furthermore, profiling of endogenously cap-snatched host messages revealed 
that these RNAs are stabilized by dDCP2 depletion. Taken together, these results 
indicate competition between cap-snatching and decapping for a common pool of 
mRNAs. Additionally, I demonstrated that this restriction is conserved in whole animals 
(flies) and in mosquito cells in tissue culture and against the distantly related bunyavirus, 
La Crosse, suggesting that in insects decapping is broadly antiviral and that cap-
snatching is an important bottleneck for bunyaviral replication. 
 Interestingly, sequencing of cap-snatched targets also revealed a preference for 
cell-cycle-related mRNAs in insects. In line with previous data from humans (144), I 
showed that P body dynamics are intricately linked to the cell cycle, and that as cells 
exist S phase and enter G2, P body size and number are significantly increased. This 
presumably occurs due to the need to degrade mRNAs encoding for DNA replication 
machinery and cell cycle progression, including replicating histone mRNAs, which are 
targeted to processing bodies for degradation by decapping. I found that arresting the 
cell cycle at S/G2, a stage when P bodies are large and enriched for cell cycle mRNAs, 
dramatically increased RVFV and LACV replication. Indeed, our genome-wide screen 
identified 28 factors that increased RVFV infection and whose depletion arrests the cell 
cycle at S/G2. Intriguingly, previous reports have found that in human cells, RVFV 
causes cell cycle arrest in S phase late during infection and that this cell cycle arrest is 
advantageous for viral output (6). As the link between P body dynamics and the cell 
cycle is conserved from insects to humans, I hypothesize that S phase arrest assists 
RVFV replication through increased targeting of cell cycle mRNAs to P bodies, where 
they are cap-snatched (Figure 5.1). It has been demonstrated that this cell cycle arrest 
during viral replication is due to viral activation of the DNA damage response (in spite of 
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a demonstrated lack of DNA damage during infection) and that chemical inhibitors of this 
pathway prevent cell cycle arrest and decrease viral replication (6), suggesting that 
prevention of cell cycle arrest may be a potential therapeutic for RVFV infection. 
 In mammals, such as mice and humans, at least two distinct cytoplasmic 
decapping enzymes have been described (117). I demonstrated that both DCP2 and 
NUDT16, the newly described and more widely expressed decapping enzyme, are 
antiviral against RVFV in humans. Through both siRNA and overexpression studies, I 
found that both DCP2 and NUDT16 affect RVFV replication, even with modest levels of 
depletion or enforced expression. This suggests that RVFV cap-snatches from a 
common pool of mRNAs targeted by these decappers. Additionally, it suggests that 
mRNA decapping is under tight regulation, as I see effects on viral replication with low 
levels of perturbation, and as stable cell lines self selected for cells with low levels of 
enforced decapper expression. 
 While both decapping enzymes are capable of restricting RVFV infection, 
profiling of endogenously cap-snatched targets in human cells revealed interesting 
effects of individual decappers on endogenous targets. I found that some targets are 
shared by both DCP2 and NUDT16 and that depletion of either causes increased 
incorporation of these targets into viral conjugates; interestingly, neither decapper 
appears able to compensate for the loss of the other, again suggesting that these 
enzymes are limiting and tightly regulated. Other targets, such as the ribosomal protein 
mRNA RPS3A, are degraded exclusively by one decapper; while NUDT16 depletion 
increased the incorporation of RPS3A into viral conjugates, DCP2 knockdown had no 
effect. This suggests that these enzymes have both redundant and specific mechanisms 
by which they are activated or through which mRNAs are targeted to them. This may 
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also suggest both overlapping and specific localization and compartments, which 
warrants further investigation. 
 While I did see evidence of cell cycle related mRNAs being endogenously cap-
snatched, unlike insect cells, where the primary mRNA targets of viral cap-snatching 
were cell cycle related, in humans I showed that predominantly, mRNAs related to host 
mRNA translation were cap-snatched. Intriguingly, during many viral infections in human 
cells, the host responds by shutting down translation; it has been demonstrated that 
other bunyaviruses, such as the hantavirus Sin Nombre, encode their own translational 
initiation activity in the N protein (84). I hypothesize that viral cap-snatching in humans 
primarily targets translation related mRNAs because they are being targeted for 
degradation by the host during infection, and that these mRNAs are targeted to areas 
where both decappers and the cap-snatching machinery compete (Figure 5.2). To this 
end, I also found that viral infection triggers loss of visible P bodies as measured by 
multiple markers. It has been demonstrated that some viruses can target stress granule 
or P body components for degradation or relocalization, thus inhibiting their formation 
(24, 39), however I found that protein levels of these markers (Dcp1a, Rck/DDX6) and 
for DCP2 itself are stable during infection, suggesting that some other mechanism 
causes these morphological changes (data not shown). Activation of decapping could 
account for these results, as increasing degradation of nucleating mRNAs would lead to 
the dissociation of microscopically visible punctae. It is also possible that P body mRNAs 
are limiting enough that viral cap-snatching itself accounts for a decreased ability of P 
bodies to nucleate. Early work examining the effects of RNA stability during bunyaviral 
infection demonstrated that RNAs have rapidly decreasing half-lives during LACV 
infection, and that even more stable mRNAs, such as actin, are degraded at an 
increased rate (104).  It was shown that these effects continue, even if viral transcription 
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is halted by cycloheximide treatment (104), suggesting that RNA instability is 
independent of viral cap-snatching and perhaps is the result of increased decapping 
activity during infection.  
 Overall, this work advances our understanding of 5’ to 3’ RNA decay and mRNA 
decapping from insects to humans. We demonstrate that specific pools are targeted by 
5’ to 3’ RNA degradation, rather than all RNAs, and we hypothesize that these pools are 
malleable depending on cellular context. Additionally, we find that specific pools of RNAs 
involved in particular programs (the cell cycle in insects and translation in mammals) are 
the targets of RVFV cap-snatching during infection and that these RNA pools overlap 
with decapping targets. This work further demonstrates that intricate interactions exist 
between RNA virus replication and RNA decay pathways and suggests that RNA decay 
components may be potential targets for therapeutic intervention in the treatment of RNA 
viral disease. 
 
2. Future Directions 
 While we focused on the interplay between mRNA decapping and viral 
transcription in our genome-wide RNAi screen, which included P body resident proteins 
and cell cycle genes, we also validated a large number of additional genes that impact 
RVFV infection. We identified two genes with roles in transcriptional pausing, dSUPT5H 
and dSUPT6H, which likely regulate the anti-RVFV transcriptional program, as we 
recently found that pausing controls antiviral defense against diverse viruses, including 
RVFV (143). Future studies can explore whether the other genes involved in 
transcription or splicing that we identified regulate antiviral gene expression programs in 
insects. Furthermore, we identified 6 of the 7 core components of the COPI coatamer as 
antiviral. COPI is involved in retrograde transport between the golgi and endoplasmic 
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reticulum, impacting secretion (Figure 3.2, Table 6.1). Although viral budding and egress 
would be attenuated by blocking secretion, the screen was not dependent on these 
processes, and therefore, it is unlikely that these steps are involved in the restriction. 
Furthermore, our readout for infection is expression of a cytoplasmic protein 
(nucleocapsid), suggesting that retrograde transport likely restricts viral infection prior to 
translation. Many RNAi screens have identified the COPI coatamer as required for 
infection, at the level of entry (19, 70) or RNA replication (31, 98), and thus we have 
potentially uncovered a new aspect of COPI-virus interactions. Further studies will reveal 
how COPI and the other genes identified impact RVFV replication. 
 In this gene set, we also identified 40 core components of the ribosome, six 
genes impacting ribosomal biogenesis and 45 genes with overall impacts on translation 
as antiviral. While human cells shut down translation in an attempt to combat some viral 
infections, we found that knockdown of translational factors in insects actually increases 
infection. Inhibition of translation via polysome disassembly has been shown to increase 
P body size in Drosophila cells (42). I hypothesize that knockdown of translational 
factors leads to increased mRNA targeting to P bodies, thus increasing P body size and 
number in a manner consistent with cell cycle arrest. Future studies will confirm whether 
this panel of genes indeed affects P body morphology; if not, clarification of the 
interactions between the translational pathway and RVFV in insects should be further 
dissected, especially since we find particular targeting of ribosomal protein RNAs for 
viral cap-snatching in human cells. 
 Our screen set out to identify factors effecting RVFV replication, which led to the 
discovery that cell cycle mRNAs are targets of both viral cap-snatching and dDCP2-
dependent decapping. This suggests pools of cell cycle RNAs are under precise control 
by dDCP2 in insects; how these particular mRNAs are targeted to dDCP2 remains 
91 
unknown. Furthermore, increasing evidence suggests that P bodies are not 
compartments of uniform composition, rather they may possess potential specializations 
since P body components only partially overlap and can be in separate structures (111, 
141). Indeed, my own studies found that while dDCP2 tightly co-localizes with RVFV, the 
canonical binding partner of dDCP2, dDCP1A only partially co-localizes with either 
dDCP2 or RVFV N (61). It is likely that in addition to specialization in their protein 
composition, these granules likely vary in their specificity for RNA targets. Therefore 
RVFV, and other bunyaviruses, may provide a useful tool for probing the RNA 
composition of subsets of granules. 
I profiled mRNA targets of RVFV in rapidly dividing cells. However, many 
bunyaviruses replicate in senescent cells, such as neurons, and RVFV is neurotropic. 
Interestingly, neurons possess specialized and extensive P body like structures termed 
“neuronal granules” that have a similar protein content and function and provide spatial 
regulation of translation (3). RNAs in these granules are sensitive to overexpression of 
DCP1A and their expression may affect synaptic plasticity and cytoskeletal organization 
(97). I hypothesize that neurotropic bunyaviruses use this pool of non-translating stored 
mRNAs for cap-snatching, and this large pool of targets may explain efficient replication 
in this cell type. Future studies will examine endogenously cap-snatched mRNA targets 
in primary rat neurons. 
To add further complexity, while Drosophila encode only one known decapper, in 
mammals there are at least two decappers (DCP2 and NUDT16), possessing both 
specific and redundant functions in mRNA decay pathways (76). This suggests a tight 
degree of regulation in both the specificity of target selection to decapping enzymes, 
which likely reside in distinct compartments, and decapping activation itself. I found that 
both overlap and specificity exist in the mRNAs targeted by these decappers in human 
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cells and their ability to restrict specific RVFV-host mRNA conjugates. While it has been 
established that NUDT16 exists both in the nucleus and the cytoplasm, whether it 
resides in P bodies or P-body-like punctae in the cytoplasm has not been described and 
is partially hampered by a lack of endogenous antibodies. Preliminary data suggest that, 
indeed, NUDT16 may exist in cytoplasmic punctae in the cytoplasm, at least in the 
context of enforced expression (Figure 4.5E). Future work will examine whether these 
punctae colocalize with known P body markers, such as DDX6 and DCP1a, DCP2 itself, 
or the viral cap-snatching machinery. I hypothesize that partial overlap exists between all 
of these compartments and that this spatial organization contributes to the specificity of 
mRNAs targeted by viral cap-snatching and by decappers. Further work should elucidate 
the regulation of RNA targeting to decapping enzyme compartments and their activation, 
as these are potentially druggable proteins.  The potential to induce decapping to restrict 
bunyaviral infection through the decay of RNA targets is exciting, as no therapeutic 
interventions currently exist for these infections. Additionally, my findings that cell cycle 
mRNA stability is specifically sensitive to decapping in insects suggests the possibility 
that decapping could be induced as a mechanism for restricting the expression of cell 
cycle regulated genes during cell cycle disregulation, including cancer. While I have 
shown that ribosomal and translation related mRNAs are primarily targeted for cap-
snatching by RVFV in humans, whether the basal levels of these RNAs are appreciably 
affected by decapping in uninfected cells remains to be established. It is possible that 
translation mRNAs are targeted specifically for decay through decapping activation as a 
means to trigger translational shutdown; I hypothesize that this specificity is mediated 
through targeted decay of TOP motif containing mRNAs. Whether the stability of 
translation related mRNAs is decay dependent endogenously, or whether this occurs 
only as a novel response to infection requires further investigation (Figure 5.2). Gene 
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regulation and control are of the utmost importance in both research and disease, and 
the technical advances achieved through the discovery of RNAi have revolutionized the 
field. The discovery that multiple decappers exist with potential target specificity points to 
new mechanisms for controlling gene programs by harnessing decapping to induce 
specific cellular mRNA decay. 
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Figure 5.1: Decapping and cap-snatching machinery compete for cell cycle regulated 
mRNAs. Left: Schematic of P body dynamics during cell cycle progression. During G1, P bodies 
(green) are present at low levels in cells. As cells exit S phase and progress into G2, P bodies 
increase in number and size (61, 144). As cell enter mitosis, P bodies are lost (144). Upper 
Inset: RVFV cap-snatching and Dcp2 mRNA decapping are competing processes. Viral mRNA 
transcription initiates upon the binding of RVFV N (red circles) to 5’caps of cellular mRNAs (blue). 
Next, RVFV L (red moons) is recruited and its endonuclease activity cleaves 10-18bp 
downstream of the cap and uses this primer to initiate viral transcription from the genomic RNA 
(black line), producing cellular-virus conjugate mRNAs (blue and red line). Dcp2 (orange) targets 
and degrades the same pool of cellular mRNAs that RVFV uses for transcription, creating a 
bottleneck. Lower Inset: During the S/G2 phase of the cell cycle, as mRNAs required for DNA 
replication are targeted for degradation (blue), this increased level of substrates alleviates the 
bottleneck, allowing the viral cap-snatching machinery to increase viral transcription (blue and red 
lines). Thus, arresting cells in S/G2 increases bunyaviral replication. 
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Figure 5.2: Decapping may restrict viral infection in humans through the decay of core 
translation mRNAs. 1. During RVFV infection, the viral infection is sensed. 2. A signaling 
cascade may potentially lead to the targeting of core translational mRNAs for decapping. 3. 
Following targeting, core translation mRNAs are degraded. 4. Decay of host translation mRNAs 
over time leads to loss of ribosome biogenesis and shutdown of host translation. 
Table  6.1. Validated hits from a genome-wide RNAi screen for genes impacting RVFV replication in Drosophila. Percent infection Z 
scores of screen hits with human homolog names, Flybase IDs, and informatics based cellular categories. Genes with cell cycle GO terms, 
S phase associated GO terms, or those that showed >30% increase in nuclear size (large nuclei) are indicated (n=2, p<0.05).  
    
PRIMARY SCREEN % 
INFECTION 
SECONDARY SCREEN 
% INFECTION           
Flybase 
Symbol 
Human 
Symbol 
Z SCORE 
1 
Z SCORE 
2 
Z SCORE 
1 
Z SCORE 
2 
Flybase Gene 
ID Placement in Figure 3.2 
Cell 
Cycle 
GO term 
S phase 
associated 
Large 
nuclei 
alphaCop COPA 1.76 3.20 4.13 3.58 FBgn0025725 COPI       
ATPsyn-beta ATP5B 1.37 2.37 6.30 5.55 FBgn0010217 Mitochondrial       
ATPsyn-
gamma ATP5C1 2.93 2.68 5.69 6.33 FBgn0020235 Mitochondrial     X 
Bap60 SMARCD1 1.76 3.46 3.41 3.33 FBgn0025463 Transcription/Chromatin       
beta'Cop COPB2 2.24 2.93 2.76 3.77 FBgn0025724 COPI       
betaCop COPB1 1.83 2.69 7.00 6.72 FBgn0008635 COPI     X 
Bx42 SNW1 3.44 2.04 4.05 4.76 FBgn0004856 Transcription/Chromatin       
c12.1 CWC15 3.85 1.45 3.49 4.50 FBgn0040235 Splicing       
cdc2 CDK1 2.64 2.93 5.51 6.35 FBgn0004106 Cell Cycle X   X 
CG10754 SF3A2 2.16 1.72 5.74 5.52 FBgn0036314 Splicing X   X 
CG11583 BRIX1 1.59 4.88 3.79 4.92 FBgn0035524 Ribosome Biogenesis       
CG13054   2.39 1.53 1.50 1.51 FBgn0036584 Other       
CG13096 RSL1D1 1.58 3.06 Ribosome FBgn0032050 Ribosome       
CG1311 SLC44A1 1.59 4.88 3.86 3.20 FBgn0035523 Membrane       
CG13705   1.90 1.38 1.70 1.99 FBgn0035582 Other       
CG14434   1.96 1.64 1.40 2.45 FBgn0029915 Other       
CG14641 RBM22 1.89 1.64 5.55 5.50 FBgn0037220 Splicing       
CG14667   1.42 3.74 1.55 1.31 FBgn0037317 Nucleic Acid Binding       
CG15220 RPA3 1.68 2.14 3.74 4.37 FBgn0030322 Cell Cycle   X   
CG1542 EBNA1BP2 1.74 4.10 4.24 5.27 FBgn0039828 Cell Cycle       
CG16903 CCNL1 2.50 3.82 6.27 4.56 FBgn0040394 Cell Cycle     X 
CG16941 SF3A1 2.88 2.37 4.99 4.48 FBgn0038464 Splicing X     
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CG1746 ATP5G2 2.36 3.04 3.21 3.46 FBgn0039830 Mitochondrial       
CG18577   1.31 1.32 1.93 2.25 FBgn0037870 Other       
CG2063 SAP30BP 1.58 4.43 5.48 5.40 FBgn0033400 Splicing     X 
CG3224 ZNF593 4.69 1.92 3.39 3.39 FBgn0029885 Nucleic Acid Binding       
CG32808 KLK7 1.61 4.29 2.75 2.88 FBgn0052808 Protein Modifications       
CG40127 RNASEK -2.01 -1.61 -5.14 -7.43 FBgn0262116 RNA decay       
CG4849 EFTUD2 4.78 2.87 6.78 5.86 FBgn0039566 Splicing       
CG6841 PRPF6 1.93 3.82 4.43 4.84 FBgn0036828 Splicing       
CG7058   1.37 2.23 1.76 1.46 FBgn0030961 Other       
CG7675 RDH14 1.66 1.55 3.50 1.37 FBgn0038610 Metabolism       
CG8097 DALRD3 1.32 1.50 1.77 1.71 FBgn0030660 Translation       
CG8108 CIZ1 2.26 1.96 2.03 1.83 FBgn0027567 Cell Cycle   X   
CG8636 EIF3G 2.60 3.89 5.40 5.39 FBgn0029629 Translation X     
CG8801 GTPBP4 1.93 3.29 3.38 4.32 FBgn0028473 Ribosome Biogenesis       
CG9667 ISY1 2.87 3.18 5.71 4.98 FBgn0037550 Splicing       
CG9715   2.29 3.04 3.53 3.38 FBgn0036668 Nucleic Acid Binding     X 
Chro   1.45 2.87 2.01 2.69 FBgn0044324 Cell Cycle       
CycA CCNA1 2.29 3.56 9.35 9.50 FBgn0000404 Cell Cycle X X X 
Dcp2 DCP2 2.12 3.52 4.57 5.08 FBgn0036534 RNA decay       
deltaCOP ARCN1 1.95 2.89 COPI Transport FBgn0028969 COPI       
Dis3 DIS3 1.52 3.35 5.04 4.56 FBgn0039183 RNA decay     X 
DMAP1 DMAP1 1.49 2.34 3.47 4.01 FBgn0034537 Transcription/Chromatin X     
E2f E2F3 1.97 2.51 2.43 2.16 FBgn0011766 Transcription/Chromatin X     
eIF-3p66 EIF3D 1.69 3.79 6.02 7.05 FBgn0040227 Translation       
eIF2B-beta EIF2B2 1.33 1.73 4.51 5.80 FBgn0024996 Translation       
gammaCop COPG 2.15 3.03 COPI Transport FBgn0028968 COPI       
geminin GMNN 2.50 4.96 8.27 7.98 FBgn0033081 Cell Cycle   X X 
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His3:CG31613 HIST2H3C 2.60 1.85 2.78 3.45 FBgn0051613 Cell Cycle   X   
His4:CG31611 HIST1H4B 1.52 1.95 3.55 3.97 FBgn0051611 Cell Cycle   X   
hoip NHP2L1 2.27 3.63 5.77 6.26 FBgn0015393 Splicing X   X 
l(1)1Bi MYBBP1A 2.26 1.81 2.50 2.67 FBgn0001341 Ribosome Biogenesis       
l(2)37Cc PHB 1.60 2.66 4.41 5.20 FBgn0002031 Mitochondrial       
LSm7 LSM7 1.36 1.96 5.27 5.12 FBgn0261068 RNA decay       
me31B DDX6 2.01 3.54 5.74 6.41 FBgn0004419 RNA decay       
mRpL27 MRPL27 2.29 3.84 Ribosome FBgn0053002 Mitochondrial       
mts PPP2CB 2.36 1.68 5.08 4.54 FBgn0004177 Cell Cycle X     
nej EP300 1.89 4.13 4.68 4.37 FBgn0261617 Cell Cycle       
Nmt NMT1 1.43 1.40 3.92 4.94 FBgn0020392 Protein Modifications       
ns1 GNL3L 2.27 5.19 4.13 5.51 FBgn0038473 Ribosome Biogenesis       
Nup62 NUP62 2.14 3.58 5.95 5.50 FBgn0034118 Nuclear Pore     X 
Pp4-19C PPP4C 2.22 2.69 3.72 3.27 FBgn0023177 Cell Cycle X     
Pros25 PSMA2 -2.14 -2.22 -6.46 -7.40 FBgn0086134 Proteasome X     
Pros26 PSMB1 -3.92 -3.20 -7.51 -5.11 FBgn0034118 Proteasome       
Prosbeta3 PSMB3 -2.81 -2.13 -4.41 -6.34 FBgn0026380 Proteasome     X 
Prosbeta5 PSMB5 -1.91 -2.01 Proteasome FBgn0029134 Proteasome X     
Prp18 PRPF18 1.53 2.87 4.44 4.89 FBgn0027784 Splicing       
qm RPL10 2.21 3.64 Ribosome FBgn0019662 Ribosome       
Rab5 RAB5A -2.96 -3.18 -3.84 -3.50 FBgn0014010 Trafficking X   X 
Rbm13 MAK16 2.11 4.15 3.23 3.34 FBgn0030067 Ribosome Biogenesis X     
Rca1   1.83 4.73 6.56 4.91 FBgn0017551 Cell Cycle X X X 
RnrS RRM2 1.61 1.30 5.13 5.49 FBgn0011704 Cell Cycle   X X 
RpA-70 RPA1 1.70 2.78 5.56 5.71 FBgn0010173 Cell Cycle X X X 
RPA2 RPA2 1.74 5.43 3.03 3.27 FBgn0032906 Cell Cycle   X X 
Rpb11 POLR2J 3.47 1.69 5.08 3.42 FBgn0032634 Transcription/Chromatin       
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Rpb5 POLR2E 1.39 3.78 4.65 5.16 FBgn0033571 Transcription/Chromatin     X 
Rpb7 POLR2G 1.61 3.51 4.09 5.94 FBgn0051155 Transcription/Chromatin     X 
Rpb8 POLR2H 2.98 2.04 6.06 5.54 FBgn0037121 Transcription/Chromatin     X 
RpII140 POLR2B 1.38 3.19 5.78 5.77 FBgn0262955 Transcription/Chromatin     X 
RpII215 POLR2A 2.98 3.48 5.65 6.57 FBgn0003277 Transcription/Chromatin       
RpL10Ab RPL10A 4.59 4.40 Ribosome FBgn0036213 Ribosome X     
RpL11 RPL11 1.68 4.44 Ribosome FBgn0013325 Ribosome X     
RpL12 RPL12 2.80 3.32 Ribosome FBgn0034968 Ribosome X     
RpL13 RPL13 1.49 3.92 Ribosome FBgn0011272 Ribosome X     
RpL15 RPL15 1.58 2.82 Ribosome FBgn0028697 Ribosome       
RpL17 RPL17 1.93 2.80 Ribosome FBgn0029897 Ribosome X     
RpL18A RPL18A 1.93 4.07 Ribosome FBgn0010409 Ribosome X     
RpL19 RPL19 2.63 4.41 Ribosome FBgn0002607 Ribosome X     
RpL21 RPL21 1.35 3.84 Ribosome FBgn0032987 Ribosome X     
RpL22 RPL22 1.90 2.90 Ribosome FBgn0015288 Ribosome X     
RpL23 RPL23 2.46 4.40 Ribosome FBgn0010078 Ribosome X     
RpL23A RPL23A 3.22 4.86 Ribosome FBgn0026372 Ribosome       
RpL24 RPL24 2.63 3.38 Ribosome FBgn0032518 Ribosome X     
RpL26 RPL26 4.73 3.00 Ribosome FBgn0036825 Ribosome X     
RpL27A RPL27A 2.29 3.84 Ribosome FBgn0261606 Ribosome       
RpL28 RPL28 1.57 1.89 3.16 2.42 FBgn0035422 Ribosome X     
RpL3 RPL3 1.88 3.68 Ribosome FBgn0020910 Ribosome X     
RpL30 RPL30 2.45 3.80 Ribosome FBgn0086710 Ribosome X     
RpL31 RPL31 2.39 4.56 Ribosome FBgn0025286 Ribosome X     
RpL32 RPL32 4.13 2.73 Ribosome FBgn0002626 Ribosome X     
RpL34a RPL34 2.76 3.98 Ribosome FBgn0039406 Ribosome       
RpL34b RPL34 2.37 4.51 Ribosome FBgn0037686 Ribosome       
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RpL35A RPL35A 3.70 1.73 Ribosome FBgn0037328 Ribosome       
RpL36 RPL36 2.21 4.14 Ribosome FBgn0002579 Ribosome       
RpL36A RPL36AL 2.47 4.95 Ribosome FBgn0031980 Ribosome X     
RpL37a RPL37 2.77 5.68 Ribosome FBgn0030616 Ribosome       
RpL37A RPL37A 2.81 5.00 Ribosome FBgn0261608 Ribosome       
RpL38 RPL38 1.62 4.61 Ribosome FBgn0040007 Ribosome       
RpL39 RPL39L 2.38 2.65 Ribosome FBgn0023170 Ribosome X     
RpL4 RPL4 2.80 4.70 Ribosome FBgn0003279 Ribosome       
RpL40 UBA52 1.74 3.65 Ribosome FBgn0003941 Ribosome       
RpL5 RPL5 1.92 3.65 Ribosome FBgn0064225 Ribosome       
RpL6 RPL6 2.36 4.72 Ribosome FBgn0039857 Ribosome       
RpL7 RPL7 1.89 4.08 Ribosome FBgn0005593 Ribosome X     
RpL7-like RPL7 2.05 2.83 Ribosome FBgn0032404 Ribosome X     
RpL9 RPL9 2.12 2.49 Ribosome FBgn0015756 Ribosome X     
RpLP0 RPLP0 2.36 2.84 Ribosome FBgn0000100 Ribosome       
RpLP2 RPLP2 5.20 3.23 Ribosome FBgn0003274 Ribosome       
RpS21 RPS21 1.72 2.87 Ribosome FBgn0015521 Ribosome       
RpS4 RPS4X 1.78 4.28 Ribosome FBgn0011284 Ribosome X     
Sam-S MAT2A 2.43 4.33 1.98 2.71 FBgn0005278 Metabolism     X 
SmB SNRPB 2.04 1.46 5.86 5.78 FBgn0262601 Splicing     X 
smt3 SUMO3 6.01 2.93 4.90 5.60 FBgn0264922 Protein Modifications     X 
Spc105R CASC5 2.02 1.57 5.59 5.03 FBgn0037025 Cell Cycle X   X 
Spt5 SUPT5H 1.67 3.28 4.49 4.34 FBgn0040273 Transcription/Chromatin X     
Spt6 SUPT6H 2.46 2.83 4.58 5.96 FBgn0028982 Transcription/Chromatin     X 
Spx SF3B4 1.32 2.73 5.19 4.69 FBgn0015818 Splicing X     
Syx7 STX7 -2.47 -4.72 -8.90 -6.59 FBgn0086377 Trafficking       
Tango4 PLRG1 3.16 3.19 6.16 5.48 FBgn0030365 Cell Cycle     X 
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zetaCOP COPZ1 2.57 3.15 COPI Transport FBgn0040512 COPI       
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